US20190338013A1 - Multi-Specific Molecules - Google Patents

Multi-Specific Molecules Download PDF

Info

Publication number
US20190338013A1
US20190338013A1 US16/079,949 US201716079949A US2019338013A1 US 20190338013 A1 US20190338013 A1 US 20190338013A1 US 201716079949 A US201716079949 A US 201716079949A US 2019338013 A1 US2019338013 A1 US 2019338013A1
Authority
US
United States
Prior art keywords
binding
antibody
protein
bdm
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/079,949
Other languages
English (en)
Inventor
George Kopsidas
Michael Ross LUKE
Phil Anthony JENNINGS
Anthony Simon ROBERTS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imunexus Pty Ltd
Original Assignee
Imunexus Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016900708A external-priority patent/AU2016900708A0/en
Application filed by Imunexus Pty Ltd filed Critical Imunexus Pty Ltd
Assigned to IMUNEXUS PTY LTD. reassignment IMUNEXUS PTY LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ROBERTS, ANTHONY, KOPSIDAS, GEORGE, LUKE, MICHAEL, JENNINGS, PHILIP ANTHONY
Publication of US20190338013A1 publication Critical patent/US20190338013A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Definitions

  • the present disclosure relates to multi-specific molecules which are capable of simultaneously binding at least two different target antigens or epitopes.
  • the molecules comprise at least one binding domain molecule (BDM) which binds to a first target antigen or epitope, the BDM being modified for selective binding to a heterologous target, coupled to a pharmacologically active protein or peptide which is an antibody or antigen-binding fragment thereof or a non-antibody protein or peptide which binds to a second target antigen or epitope, the BDMs being coupled to a C-terminus of a polypeptide present within the pharmacologically active protein or peptide.
  • BDM binding domain molecule
  • proteins in their unmodified form are known to be rapidly removed in vivo either by renal filtration, cellular clearance mechanisms in the reticulendothelial system, or proteolytic degradation (Francis (1992) Focus on Growth Factors 3: 4-11).
  • Various modifications of proteins and peptides have been developed to increase the therapeutic protein's stability, circulation time and biological activity (see Francis (1992) Focus on Growth Factors 3: 4-10).
  • Francis (1992) Focus on Growth Factors 3: 4-10 there exists a need in the art for mechanisms which allow such therapeutic proteins to subsist in vivo for longer.
  • antibody products Therapeutic monoclonal antibodies and antibody-related products such as antibody-fusion proteins, antibody fragments, and antibody-drug conjugates (collectively referred to hereafter as antibody products) have grown to become the dominant product class within the biopharmaceutical market.
  • Antibody products today are approved for the treatment of a variety of diseases, including some cancers, multiple sclerosis, asthma and rheumatoid arthritis to name but a few.
  • a bi-specific is generally an engineered protein that is composed of two different antibodies or antibody-like fragments (known as antibody-like scaffolds) that are fused together so that the bi-specific can bind to two different types of targets at the same time (i.e. two specificities).
  • antibody like scaffolds are generally constructed from fragments of antibodies or made from antibody like proteins that, like antibodies, can bind to specific targets.
  • Dual specificity antibodies allow for more potent antibody drugs which can be designed to redirect and activate immune effector cells such as T-cells to specifically kill tumours; bind to multiple targets and effect multiple pathogenic pathways; bind to multiple sites on the one target cell or protein to increase specificity or induce synergistic induction; and target tumours that are heterogeneous in nature.
  • bi-specific has a number of significant drawbacks: Firstly, the small size of bi-specifics created by fusing two or more antibody-like scaffolds together, are generally significantly below the renal threshold and typically show very short blood circulation half-life which is in the range of minutes to hours. Such a short half-life necessitates dosing intervals of every day or via constant infusion which can lead to exceeding the toxicity threshold of the drug. And secondly, the affinity of many antibody-like scaffolds for their target is inadequate due to their monovalent nature (i.e. they have only one antigen binding site compared to antibodies which have two). Full antibodies bind with both antigen binding sites improving the overall strength of binding (knows as an avidity effect) giving a certain advantage compared with monovalent antibody-like scaffolds.
  • the present disclosure is based on approaches to improve one or more characteristics of a protein or peptide, including an antibody or an immunoglobulin antigen-binding fragment.
  • the present disclosure is based on approaches that improve a poorly therapeutic protein (e.g. therapeutic antibody) by converting it into a multi-specific format.
  • Coupling the protein or peptide to at least one binding domain molecule (BDM) described herein provides a bi-specific or multi-specific molecule thus allowing the molecule to bind to different targets by virtue of exploiting the different binding targets (i.e. antigens or epitopes) of the protein and the BDM.
  • binding targets i.e. antigens or epitopes
  • one or more characteristics of the protein or peptide can be improved including therapeutic efficacy, half-life, immune engagement, avidity, cellular penetration and/or tolerability.
  • the molecules thus provide an alternative to traditional bi-specific antibodies.
  • the target antigen or epitope bound by the BDM is different to the target antigen or epitope bound by the protein or peptide.
  • the protein may bind to a target antigen or epitope present on a cell or tissue and the BDM may bind to a target antigen or epitope present on an immune-modulating cell such as a cytotoxic T cell or protein to facilitate cell killing, or a target antigen on human serum albumin (HSA) so that the half-life of the protein or peptide may be extended.
  • an immune-modulating cell such as a cytotoxic T cell or protein to facilitate cell killing, or a target antigen on human serum albumin (HSA) so that the half-life of the protein or peptide may be extended.
  • HSA human serum albumin
  • the therapeutic efficacy of the protein or peptide can be promoted by utilising the functionality of the target to which the BDM binds.
  • the protein or peptide can be converted into bi-specific, tri-specifics or even multi-specifics.
  • the smaller size, binding affinity characteristics and solubility of the BDMs make them ideal agents for improving the efficacy of poorly therapeutic proteins or peptides, for example, facilitating the body's natural immunological mechanism for destroying tumour cells.
  • the present disclosure thus provides a multi-specific molecule capable of binding to two or more different target antigens or epitopes, the molecule comprising:
  • BDM binding domain molecule
  • VLD V-like domain
  • a pharmacologically active protein or peptide which is an antibody or antigen-biding fragment thereof or a non-antibody protein or peptide which binds to a second target antigen or epitope;
  • the at least one BDM is coupled to a C-terminus of a polypeptide present within the pharmacologically active protein or peptide.
  • the pharmacologically active protein binds to its native target antigen or epitope.
  • the epitopes are on separate antigens.
  • the first and second target antigens are different. In one example, the first and second target antigens are the same but the molecule binds to different epitopes on the target antigen. In one example, the first and second target epitopes are different.
  • the molecule is a bi-specific. In one example, the molecule is a tri-specific.
  • the molecule comprises one, two, three, four or five BDMs (or multiples thereof e.g. BDM dimers). In another example, the molecule comprises one pair or two pairs of BDMs, wherein the BDMs in the pair are identical. In one example, one, two or three BDMs (or multiples thereof e.g. dimers) are coupled to the non-antibody protein or peptide.
  • the molecule comprises least two BDMs, or at least one pair of BDMs, wherein each BDM (or BDM pair) binds to a different target antigen or epitope.
  • each BDM (or BDM pair) binds to a target antigen or epitope that is different from the target antigen or epitope to which the pharmacologically active protein or peptide binds.
  • two, four, six, or eight BDMs are coupled to the full length antibody, wherein the molecule binds to at least two different target antigens or epitopes. In one example, the molecule binds to two different target antigens or epitopes. In another example, the molecule binds to three different target antigens or epitopes. In another example, the molecule binds to four different target antigens or epitopes.
  • the pharmaceutically active protein is a full length antibody or an immunoglobulin antigen-binding fragment thereof.
  • the protein is a non-antibody protein or peptide.
  • the non-antibody protein or peptide is selected from the group consisting of a blood clotting factor, an anticalin, a toxoid, a collagen binding protein, a human serum binding protein (e.g. Human serum albumin, HSA) a tumour necrosis factor (TNF)-alpha receptor binding protein, an integrin binding protein, a vascular endothelial growth factor (VEGF) or mimetic thereof, an erythropoietin (EPO) or mimetic thereof, a C4 binding protein, a urokinase receptor antagonist, a lymphokine, a cytokine, an osteoprotegerin (OPG), or the extracellular domain of a protein selected from programmed cell death 1 protein (PD1), programmed death ligand 1 (PD-L1), NKG2D, MHC class I polypeptide related sequence A (MICA), MHC class I polypeptide related sequence B (MICB), UL16 binding protein (ULBP).
  • PD1 programme
  • the blood clotting factor is factor VIII or factor IX.
  • the toxoid is botulinium toxoid.
  • the lymphokine is IL-2 or mimetic thereof or GM-CSF or mimetic thereof.
  • the cytokine is a G-CSF or mimetic thereof or stem cell factor (SCF) or a mimetic thereof.
  • SCF stem cell factor
  • the molecule comprises one BDM coupled to the non-antibody protein.
  • the ratio of BDM to non-antibody protein is 1:1.
  • the at least one BDM is coupled to a C-terminus of an antibody heavy chain polypeptide. In one example, the at least one BDM is coupled to a C-terminus of both antibody heavy chain polypeptides.
  • the at least one BDM is coupled to a C-terminus of an antibody light chain polypeptide. In one example, the at least one BDM is coupled to a C-terminus of both antibody light chain polypeptides.
  • the at least one BDM is coupled to a C-terminus of all antibody heavy and light chain polypeptides.
  • the at least one BDM is coupled to a C-terminus of the CH1, CH2 or CH3 domain of an antibody heavy chain polypeptide.
  • the at least one BDM is coupled to a C-terminus of an antibody Fc.
  • At least one BDM is coupled to:
  • the full length antibody or immunoglobulin antigen-binding fragment according to the present disclosure may itself be mono-specific or bi-specific.
  • a mono-specific antibody it is meant that the antibody binds to a single target or epitope through complementarity heavy and light chain variable domains (i.e. a pair of V H /V L ) which share the same specificity for the target antigen or epitope.
  • Bi-specific antibodies comprise one V H /V L pair on each arm of the Y shaped antibody molecule, wherein each V H /N L binds to a different target antigen or epitope.
  • a full length antibody comprises two heavy chains and two light chains, each forming a pair. Accordingly, in one example, the ratio of antibody chains to BDMs is 4:2. In one example, the molecule comprises four BDMs coupled to an antibody (i.e. one BDM on each light chain and one BDM on each heavy chain). In one example, the ratio of antibody chains to BDMs is 4:4. In one example, the molecule comprises six BDMs coupled to an antibody. In one example, the ratio of antibody chains to BDM is 4:6. In another example, the molecule comprises eight BDM coupled to an antibody. In another example, the ratio of antibody chains to BDM is 4:8. In another example, the ratio of antibody chains to BDMs is 4:2 n wherein n is a number between 1 and 5, including 1 and 5.
  • the immunoglobulin antigen-binding fragment is selected from the group consisting of Fab, F(ab′) 2 , Fab′, scFv, di-scFv, or chemically linked F(ab′) 2 .
  • the molecule comprises a single BDM coupled to an immunoglobulin antigen-binding fragment.
  • the ratio of immunoglobulin antigen binding fragment chains to BDM is 2:1.
  • the ratio of immunoglobulin antigen-binding fragment chains to BDM is 2:2.
  • a chain of BDMs may be coupled to the antigen-binding fragment wherein the ratio of immunoglobulin antigen binding fragment chains to BDM is 2:n wherein n is number between 1 and 16.
  • n is a number between 1 and 14, between 1 and 12, between 1 and 10, between 1 and 8, between 1 and 4, or 2, or 1.
  • the present disclosure contemplates a number of different configurations in which the at least one BDM may be coupled to a full length antibody, for example:
  • At least one BDM is coupled to a C-terminus of a CH3 domain of a heavy chain polypeptide of an antibody
  • At least one BDM is coupled to a C-terminus of a CH1 domain of a light chain polypeptide
  • At least one BDM is coupled to a C-terminus of a CH3 domain of a heavy chain polypeptide and to a C-terminus of a CH1 domain of a light chain polypeptide;
  • At least one BDM is coupled to the C-terminus of a CH3 domain of both heavy chain polypeptides
  • At least one BDM is coupled to the C-terminus of a CH1 domain of both light chain polypeptides.
  • an BDM may be coupled to a C-terminus of either the heavy or light chain of the immunoglobulin fragment.
  • an BDM may be coupled to a C-terminus of both the heavy and light chains of the immunoglobulin fragment.
  • the BDM may be coupled to a constant domain (e.g. CH1) of either the light and/or heavy chains of the immunoglobulin fragment (e.g. Fab).
  • At least one BDM is coupled to a C-terminus of the constant region of a light chain polypeptide of an Fab
  • At least one BDM is coupled to a C-terminus of the CH1 of the heavy chain polypeptide of an Fab
  • the BDM preferably comprises or consists of a scaffold having three exposed binding loops (BLs) contained within.
  • the scaffold may be selected from the group consisting of an immunoglobulin-like (Ig-like) domain containing superfamily member, a V-like domain, an i-body, VNAR or VHH.
  • the exposed BL sequences are modified or replaced from the native BL sequences to provide altered binding loops with selective binding to a heterologous target antigen or epitope.
  • binding loops are designated BL1, BL2 and BL3 respectively as illustrated in FIG. 1A .
  • the BLs are analogous to the CDR1, CDR2 and CDR3 regions of an antibody variable region.
  • BL1 and BL3 are modified or replaced from the native BL sequence. In another example, BL1, BL2 and BL3 are modified or replaced from the native BL sequence.
  • the BDM scaffold has less than about 20% sequence identity to a human immunoglobulin variable region domain, said scaffold having two or more altered BLs and exhibiting selective binding to a heterologous target antigen or epitope.
  • the Ig-like domain containing superfamily member may be selected from the group consisting of a V-like domain (VLD), C-set domain, a ThyOx family member polypeptide, a T cell receptor, CD2, CD4, CD8, class I MHC, class II MHC, CD1, cytokine receptor, G-CSF receptor, GM-CSF receptor, hormone receptors, growth hormone receptor, erythropoietin receptor, interferon gamma receptor, prolactin receptor, NCAM, VCAM, ICAM, N-caderin, E-caderin, fibronectin, tenascin, and I-set containing domain polypeptides or a functional fragment thereof.
  • VLD V-like domain
  • C-set domain a ThyOx family member polypeptide
  • a T cell receptor CD2, CD4, CD8, class I MHC, class II MHC, CD1, cytokine receptor, G-CSF receptor, GM-CSF receptor, hormone receptors, growth hormone receptor, ery
  • the BDM scaffold according to the present disclosure may be selected from the group consisting of V-like domain (VLD), a C1 set domain or C2 set domain. Combinations of BDMs coupled to the protein or peptide are also contemplated. By way of illustration, one BDM may be a VLD and another BDM may be C set domain.
  • VLD V-like domain
  • C1 set domain C1 set domain
  • C2 set domain Combinations of BDMs coupled to the protein or peptide are also contemplated.
  • one BDM may be a VLD and another BDM may be C set domain.
  • the BDM scaffold comprises or consists of the extracellular portion of a native VLD, or a VLD having altered binding loops (i.e. modified BDM) relative to the native VLD, wherein the VLD is from a protein selected from the group consisting of ACAN, ADORA3, ALCAM, JAML, AMIGO1, AXL, basigin, BCAM, BTNL2, 3, 8, 9 or 10, butyrophilin (BTN), cell adhesion molecule (CAM), CD2, CD4, CD7, CD8, CD28, CD33, CD48, CD79, CD80, CD83, CD86, CD101, CD112, CD226, CD274, CD276, CD300, carcinoembryonic antigen-related cell adhesion molecule (CEACAM), CRTAM, CTLA4, CXADR, C10orf54, ERMAP, ESAM,
  • CEACAM carcinoembryonic antigen-related cell adhesion molecule
  • HPLN Hyaluronan and proteoglycan link protein
  • HAVCR1 HEPACAM
  • HHLA2, HSPG2, ICOS
  • the BDM scaffold comprises or consists of the extracellular portion of a native C-set domain (C1-set or C2-set domain), or a C-set domain having altered binding loops (i.e. modified C-set domain) relative to the native C-set domain, wherein the C-set domain is from a protein selected from the group consisting of AZGP1; basigin, B2M; CEACAM1, 3, 4, 5, 6, 7, 8; CD1A; CD1 B; CD1C; CD1 D; CD1 E; DMA; DQB2; DRB1; ELK2P1; FCGRT; HFE; HHLA2; HLA-A; HLA-B; HLA-B35; HLA-B57; HLA-C; HLA-CW; HLA-Cw; HLA-D; HLA-DMA; HLA-DMB; HLA-DOA; HLA-DOB; HLA-DP; HLA-DPA1; HLA-DPB1; HLA-DQA1; H
  • the BDM scaffold comprises or consists of the whole or part thereof of a native Ig-like domain or an Ig-like domain with altered binding loops (i.e. modified Ig-like domain) relative to the native Ig-like domain, wherein the Ig-like domain is selected from the group consisting of a ThyOx family member polypeptide, a T cell receptor, CD2, CD4, CD8, class I MHC, class II MHC, CD1, cytokine receptor, G-CSF receptor, GM-CSF receptor, hormone receptors, growth hormone receptor, erythropoietin receptor, interferon gamma receptor, prolactin receptor, NCAM, VCAM, ICAM, N-caderin, E-caderin, fibronectin, tenascin, and I-set containing domain polypeptides or a functional fragment thereof.
  • a ThyOx family member polypeptide a T cell receptor
  • CD2, CD4, CD8 class I MHC, class II MHC, CD1, cytokin
  • modified VLD refers to a BDM in which at least two, and preferably all three of the exposed binding loops are altered to provide binding to a heterologous target antigen or epitope.
  • the alteration may be achieved by amino acid substitution or replacement of the whole or part thereof of individual binding loops.
  • the altered amino acid sequences in the binding loops confers selective binding activity towards a target antigen other than that bound by the unaltered Ig-like domain containing scaffold.
  • the amino acid alterations can be made at the nucleic acid or polypeptide level using methods known in the art.
  • a VLD or C-set domain may encompass a BDM which binds to a heterologous target antigen or epitope.
  • a modified VLD or C-set domain may also comprise one or more modifications which alter the affinity of the BDM to its native target. The affinity towards the native target may be increased or decreased compared to the native VLD or C-set domain.
  • the modified BDM comprises or consists of a sequence at least about 60%, 70%, 75%, 80%, 85%, 87%, 90%, or 95% identical to the sequence of a native VLD or C-set domain.
  • the BDM comprises or consists of the whole or part thereof of a VLD protein or C-set domain protein comprising between 5 and 30 amino acid substitutions, between 5 and 20 amino acid substitutions, between 5 and 15 amino acid substitutions, between 5 and 10 amino acid substitutions, or up to 5 amino acid substitutions compared to the corresponding native VLD or C-set domain protein.
  • the BDM is not the CLTA-4 VLD mutant molecule L104EA29Y or L104E described in U.S. Pat. No. 7,094,874.
  • the modified BDM comprises one heterologous BL sequence. In another example, the modified BDM comprises two heterologous BL sequences. In yet another example, the BDM comprises three heterologous BL sequences.
  • the BDM is a VLD scaffold comprising or consisting of the extracellular portion of CTLA4, CD28 or ICOS.
  • the VLD scaffold is the extracellular portion of human CTLA4.
  • the BDM VLD comprises or consist of the sequence set forth in
  • the alanine (A) at position 31 is substituted with tyrosine (Y).
  • the methionine (M) at position 56 is replaced with a threonine (T).
  • the BDM VLD scaffold consists of a framework sequence corresponding to residues 1 to 25, 34 to 54, 60 to 96 and 106 to 126 of SEQ ID NO:1.
  • the BDM scaffold comprises or consists of a sequence having at least about 70% sequence identity thereto, or at least 75%, 80%, 85%, 87%, 90%, 92%, 93%, 94%, 95%, 96%, 97% 98% or 99% identity to SEQ ID NO:1 or to residues 1 to 25, 34 to 54 and 60-107 and 116 to 136 of SEQ ID NO:1.
  • a single exposed binding loop, two exposed binding loops or all three exposed binding loops of the native BDM scaffold may be modified by amino acid substitution, addition or deletion, and/or by any change to one or more physical characteristics (e.g. size, shape, charge, hydrophobicity etc.).
  • the exposed binding loop (BL1) sequence ASPGKATE (SEQ ID NO:2) or ASPGKYTE (SEQ ID NO:7), and/or exposed loop (BL2) sequence MMGNE (SEQ ID NO:3) and/or the exposed binding loop (BL3) sequence ELMYPPPYY (SEQ ID NO:4) of the native human CTLA-4 VLD sequence is modified by amino acid substitution, addition or deletion or replaced with a heterologous sequence.
  • amino acid residues at positions 26 to 33, and/or positions 55 to 59 and/or positions 98 to 105 of SEQ ID NO:1 are modified or replaced.
  • amino acid residues at positions 27 to 33, and/or positions 54 to 62 and/or positions 98 to106 of SEQ ID NO:1 are modified or replaced with heterologous sequence.
  • the effect of modifying the native human CTLA-4 VLD is to abolish the natural affinity of the VLD to CD80 and CD86.
  • the BDM VLD scaffold comprises or consists of the sequence
  • the BDM VLD scaffold comprises or consists of the sequence
  • the BL-1, BL-2 and BL-3 of the BDM comprise or consist of respectively ASPGKATE (SEQ ID NO:2) or ASPGKYTE (SEQ ID NO:7), MMGNE (SEQ ID NO:3) and ELMYPPPYYL (SEQ ID NO:9), wherein the BDM binds to B7-1.
  • the BL-1, BL-2 and BL-3 of the BDM of the molecule comprise or consist of respectively TVSWVDME (SEQ ID NO:10), WNGRW (SEQ ID NO:11) and QLDPSWGYYWQGYE (SEQ ID NO:12), wherein the BDM binds to sclerostin.
  • the BDM VLD comprises or consists of the sequence KAMHVAQPAVVLASSRG IASFVCEYASPGKYTEVRVTVLRQADSQVTEVCAATYMTGNELTFL DDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYLGIGNGTQIYVIDPEPSPDSN (SEQ ID NO:13), wherein the BDM binds to B7-1.
  • the BDM VLD comprises or consists of the sequence KAMHVAQPAVVLASSRG IASFVCEYTVSWVDM EVRVTVLRQADSQVTEVCAATYWNGRWLT FLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVQLDPSWGYYWQGYEG IGNGTQIYVIDPE PSPDSN (SEQ ID NO:14), wherein the BDM binds to sclerostin.
  • BL-1, BL-2 and BL-3 of the BDM are replaced with the CDR1, CDR2 and CDR3 sequences respectively of an antibody.
  • the antibody from which the CDR sequences are derived may be derived from any species.
  • the antibody is derived from a human.
  • the antibody is derived from a domestic animal, for example, cat, dog, rabbit, guinea pig or horse.
  • the at least one BDM may be present in the molecule in monomeric form or dimeric form. In another example, the at least one BDM may consist of a series of BDM monomers linked together.
  • the BDM is a dimer.
  • the dimer may be formed through a disulphide bond between cysteine residues (Cys 120 ) in the stalks of the CTLA4 monomers (each stalk corresponding to about 10 residues connecting the VLD to the transmembrane region).
  • the dimer may be formed by linking of monomeric units.
  • a series (or daisy chain) of monomeric BDMs may be linked together. For example, between 2 and 16
  • BDM monomers may be joined head-to-tail in a daisy chain like arrangement.
  • between 2 and 14, between 2 and 12, between 2 and 10, between 2 and 8, or between 2 and 4 BDMs are joined head to tail.
  • Linking of BDM monomers may be achieved for example by use of covalent or non-covalent bonds or by use of a short peptide linker as described further herein. Any of the linking methodologies referred to herein can be employed to link the BDM monomers together. Alternatively adjacent BDM monomers may be directly fused together.
  • the BDM is soluble.
  • the ‘solubility’ of the BDM scaffold of the present disclosure correlates with the production of correctly folded, monomeric domains.
  • the solubility may be assessed for example, by high performance liquid chromatography (HPLC).
  • HPLC high performance liquid chromatography
  • soluble, monomeric BDMs will give rise to a single peak on the HPLC chromatograph, whereas insoluble (e.g. multimeric or aggregated) BDMs will give rise to a plurality of peaks.
  • Coupling of the at least one BDM and the pharmacologically active protein may be achieved by methods known to persons skilled in the art. Coupling may be achieved, for example, by use of a linker, by direct fusion, by conjugation or by covalent or non-covalent bonding.
  • coupling of the pharmacologically active protein and the at least one BDM is achieved by means of a peptide linker.
  • a peptide linker Any suitable peptide linker known in the art can be utilised in the present disclosure.
  • the linker comprises a sequence (SGGGG) n S, (SEQ ID NO:15) wherein n is any number from 2 to 8, or from 3 to 6 or from 3 to 4.
  • the linker comprises or consists of the sequence
  • coupling of the pharmacologically active protein and the at least one BDM is achieved without use of a linker.
  • the molecule is capable of simultaneous binding to the first, second and/or optionally a third target antigen.
  • the molecule is capable of simultaneous binding to B7-1-Fc and sclerostin.
  • the pharmacologically active protein or peptide and the at least one BDM specifically bind to their respective target antigens.
  • the molecule binds selectively to cells that express two or more different target antigens or epitopes recognised by the individual BDM and pharmaceutically active protein moieties of the molecule but not to cells that express only one of the target antigens or epitopes.
  • the present disclosure also provides a polypeptide comprising a BDM scaffold coupled to a pharmacologically active protein or peptide.
  • the polypeptide further comprises a linker.
  • the linker comprises a sequence (SGGGG)nS, wherein n is any number from 2 to 8, or from 3 to 6 or from 3 to 4.
  • the linker comprises or consists of the sequence SGGGGSGGGGSGGGGS (SEQ ID NO:16) or SGGGGSGGGGSGGGGSGGGGS (SEQ ID NO:17).
  • the present disclosure also provides a polypeptide selected from the group comprising or consisting of a sequence of any one of SEQ ID NOs: 5, 6, 13, 14, 19, 21, 22, 23, 24, 25, 27, 28 or 29.
  • the polypeptide is isolated.
  • a polypeptide of the present disclosure includes a polypeptide tag. Examples, of suitable tags include, but are not limited to the p97 molecule, myc, hexa-his tag, flag, E7.
  • the molecule according to the disclosure is a nucleic acid.
  • the present disclosure also provides a nucleic acid encoding a polypeptide of the present disclosure, in particular a polypeptide of any one of SEQ ID NOs: 5, 6, 13, 19, 21, 22, 23, 24, 25, 27, 28 or 29.
  • Nucleic acid can comprise DNA or RNA or both.
  • the molecule comprises or consists of the nucleic acid sequence of a BDM VLD set forth in:
  • N1 is length of nucleotides encoding a first binding loop
  • N2 is a length of nucleotides encoding a second binding loop
  • N3 is a length of nucleotides encoding a third binding loop.
  • N1, N2 and N2 are between 15 and 45 nucleotides.
  • N1 is between 15 and 24 nucleotides.
  • N2 is 15 nucleotides and N3 is between 30 and 45 nucleotides.
  • N is any nucleotide (A, C, T, G).
  • the nucleic acid is provided in an expression construct in which the nucleic acid is operably linked to a promoter.
  • an expression construct can be in a vector e.g. a plasmid.
  • the expression construct may be a bicistronic expression construct.
  • the present disclosure also contemplates separate expression constructs for the heavy and light chains of the antibody or immunoglobulin antigen-binding fragment.
  • one vector may comprise a nucleic acid encoding the immunoglobulin light chain and a BDM VLD and the other which comprises a nucleic acid encoding the immunoglobulin heavy chain or vice versa.
  • the nucleic acid may further include a moiety e.g. FLAG to facilitate purification and identification.
  • a moiety e.g. FLAG to facilitate purification and identification.
  • the present disclosure also provides a host cell transformed with a nucleic acid described herein.
  • Suitable host cells include bacteria, mammalian cells, yeast, moss (bryophytes), and baculovirus systems.
  • the present disclosure also provides a method for producing the polypeptide molecule of the present disclosure comprising culturing the host cell of the present disclosure under conditions enabling expression of the polypeptide and optionally recovering the polypeptide.
  • the polypeptide may be glycosylated or unglycosylated.
  • the present disclosure also provides a method for making a multi-specific molecule comprising at least one BDM VLD coupled to a pharmacologically active protein, the method comprising:
  • the present disclosure also provides a method or making a multi-specific molecule comprising at least one BDM VLD coupled to an antibody, the method comprising:
  • the antibody heavy chain consists of the full length sequence. In another example according to the method, the antibody heavy chain consists of the variable region and at least the CH1 region. In another example, the antibody heavy chain consists of the variable region and at least the CH1 and CH2 regions.
  • no linker sequence is present and the nucleic acid sequences of the pharmacologically active protein or peptide and BDM VLD are contiguous. In another example, no linker sequence is present and the nucleic acid sequences encoding the antibody heavy and/or light chain and BDM sequences are contiguous.
  • the antibody nucleic acid sequence may further comprise the hinge region.
  • the present disclosure also provides a vector(s) comprising one or more nucleic acid sequences described herein.
  • the vector comprises a nucleic acid sequence encoding a pharmacologically active protein as described herein and the BDM VLD and optionally a nucleic sequence encoding the linker.
  • the vector(s) comprises a nucleic acid sequence encoding an antibody light or heavy chain as described herein and a nucleic acid sequence encoding an BDM VLD and optionally a nucleic acid sequence encoding the linker.
  • the vector(s) comprises nucleic acid sequences encoding both the antibody heavy and light chains as described herein and a nucleic acid sequence encoding a BDM VLD and optionally a nucleic acid sequence encoding the linker.
  • the present disclosure also provides a host cell containing a vector or containing one or more nucleic acid sequences described herein.
  • the present disclosure also provides a multi-specific molecule produced by a method described herein.
  • the molecule of the present disclosure may be provided in a composition. Accordingly, in another embodiment, the present disclosure provides a pharmaceutical composition comprising the multi-specific molecule described herein, together with a pharmaceutically acceptable carrier and/or excipient.
  • the composition may be provided as a medicament.
  • the composition is for use in the treatment of a disorder.
  • the composition is for anti-ageing or as a cosmetic.
  • the molecule may be labelled with an agent to facilitate detection.
  • composition of the present disclosure may also be provided in the form of a kit with instructions for use according to a particular treatment indication.
  • the present disclosure also provides use of the multi-specific molecule as described herein for detection of one or more target antigens to which one or more moieties of the molecule bind.
  • FIG. 1 provides (A) a schematic of the sequence of the native human CTLA4 VLD scaffold showing where the framework sequences and the sequences of binding loops 1, 2 and 3 are located (designated as BL1, BL2 and BL3).
  • B shows the location of the binding loop replacements in the CTLA4 VLD wherein BL1 is designated by Xn 1 , BL2 is designated by Xn 2 and BL3 is designated by Xn 3 wherein X is any amino acid and n is a number between 5 and 15.
  • C shows the sequence of the sclerostin human VLD scaffold wherein the sequence of the binding loop regions are underlined.
  • FIG. 2 shows a schematic of an antibody-VLD bi-specific molecule according to one example of the disclosure.
  • the antibody binds to target A via its heavy and light chain V domains.
  • the VLDs which are attached to the C-terminus CH3 constant domain of the antibody heavy chain bind to Target B.
  • the bi-specific can bind to both Target A and B either individually or at the same time.
  • FIG. 3 shows a schematic of an antibody-VLD bi-specific molecule according to one example of the disclosure.
  • the antibody binds to Target A via its heavy and light chain V domains.
  • a VLD is attached at the C-terminus of each constant domain of the light chain (constant light, CL) and binds to Target B.
  • CL constant light
  • FIG. 4 shows a schematic of an antibody-VLD tri-specific molecule according to one example of the disclosure.
  • the antibody binds to Target A via its heavy and light chain V domains.
  • a VLD is attached to the C-terminus of each light chain constant domain (CL) and heavy chain constant domain (CH3).
  • the tri-specific can bind to Target A and B and C either individually or at the same time or in a combination of the three targets (e.g. Target A and B or Target A and C or Target B and C).
  • FIG. 5 shows a schematic of an Fab-VLD bi-specific molecule according to one example of the disclosure.
  • the Fab binds to Target A via its heavy and light chain V domains.
  • a VLD is attached to the C-terminus of the heavy chain constant domain (CH1) and binds to Target B.
  • the bi-specific can bind to both Target A and B either individually or at the same time.
  • FIG. 6 shows a schematic of the Fab-VLD bi-specific molecule according to one example of the disclosure.
  • the Fab binds to Target A via its heavy and light chain V domains.
  • a VLD is attached to the C-terminus of the light chain constant domain (CL) and binds to Target B.
  • the bi-specific can bind to both Target A and B either individually or at the same time.
  • FIG. 7 shows a schematic of the Fab-VLD tri-specific molecule according to one example of the disclosure.
  • the Fab binds to Target A via its heavy and light chain V domains.
  • a VLD is attached to the C-terminus of the light chain constant domain (CL) and binds to Target B and a VLD is attached to the C-terminus of the heavy chain constant domain (CH1) and binds to Target C.
  • the tri-specific can bind to Target A and B and C either individually or at the same time or in a combination of the three targets (e.g. Target A and B or Target A and C or Target B and C).
  • FIG. 8 shows the expression (SDS PAGE) under non-reducing conditions of the parent D1.3 Fab, and the bi-specific and tri-specific variants.
  • D1.3 Fab is the anti-lysozyme Fab
  • D1.3 Fab-VLDx1 (HC) is the anti-lysozyme Fab with a VLD fused to the CH1 domain of the heavy chain
  • D1.3 Fab-VLDx1 (LC) is the anti-lysozyme Fab with a VLD fused to the CL domain of the light chain
  • D1.3 Fab-VLDx2 (HC+LC) is the anti-lysozyme Fab with VLDs fused to the CH1 domain of the heavy chain and to the CL domain of the light chain.
  • FIG. 9 shows SDS PAGE expression analysis under reducing conditions of the parent D1.3 Fab, the bi-specific and tri-specific variants.
  • D1.3 Fab is the anti-lysozyme Fab
  • D1.3 Fab-VLDx1 (HC) is the anti-lysozyme Fab with a VLD fused to the CH1 domain of the heavy chain
  • D1.3 VLDx1 (LC) is the anti-lysozyme Fab with a VLD fused to the CL domain of the light chain
  • D1.3 VLDx2 (HC+LC) is the anti-lysozyme Fab with VLDs fused to the CH1 domain of the heavy chain and to the CL domain of the light chain.
  • FIG. 10 shows BLitz analysis of initial binding of the bi-specific [IgG VLDx2 (HC)] to streptavidin captured biotin labelled lysozyme followed by secondary binding to B7.1-Fc.
  • the bi-specific has B7-1 binding VLDs fused to the D1.3 antibody [D1.3 IgG] heavy chains.
  • Trace 1 is the D1.3 anti-lysozyme antibody binding to lysozyme immobilised on the biosensor surface followed by an addition of Buffer at Point 1.
  • Trace 2 is the D1.3 anti-lysozyme antibody binding to lysozyme followed by an addition of B7-1-Fc at Point 1.
  • B7-1-Fc was replaced with Buffer at Point 2.
  • Trace 3 is the bi-specific—D1.3 IgG-VLDx2 (HC) binding to lysozyme immobilised on the biosensor surface followed with an addition of buffer at Point 1.
  • Trace 4 is the bi-specific—D1.3 IgG-VLDx2 (HC) binding to lysozyme immobilised on the biosensor surface followed by an addition of B7-1-Fc at Point 1. B7-1-Fc was replaced with Buffer at Point 2. The sensorgram demonstrates simultaneous, dual target binding to lysozyme and B7-1-Fc.
  • FIG. 11 shows BLitz analysis of initial binding of the bi-specific [IgG VLDx2 (LC)] to streptavidin captured biotin labelled lysozyme followed by secondary binding to B7-1-Fc.
  • the bi-specific has B7-1 binding VLDs fused to the D1.3 antibody [D1.3 IgG] light chains.
  • Trace 1 is the D1.3 anti-lysozyme antibody binding to lysozyme immobilised on the biosensor surface followed by an addition of Buffer at Point 1.
  • Trace 2 is the D1.3 anti-lysozyme antibody binding to lysozyme immobilised on the biosensor surface followed by an addition of B7-1-Fc at Point 1.
  • B7-1-Fc was replaced with Buffer at Point 2.
  • Trace 3 is the bi-specific—D1.3 IgG-VLDx2 (LC) binding to lysozyme immobilised on the biosensor surface followed with an addition of buffer at Point 1.
  • Trace 4 is the bi-specific—D1.3 IgG-VLDx2 (LC) binding to lysozyme immobilised on the biosensor surface followed by an addition of B7-1-Fc at Point 1. B7-1-Fc was replaced with Buffer at Point 2. The sensorgram demonstrates simultaneous, dual target binding to lysozyme and B7-1-Fc.
  • FIG. 12 shows BLitz analysis of initial binding of the tri-specific [IgG VLDx4 (HCLC)] to streptavidin captured biotin labelled lysozyme followed by secondary binding to B7-1-Fc.
  • the tri-specific has B7-1 binding VLDs fused to both the D1.3 antibody [D1.3 IgG] heavy chains and light chains.
  • Trace 1 is the D1.3 anti-lysozyme antibody binding to lysozyme immobilised on the biosensor surface followed by an addition of Buffer at Point 1.
  • Trace 2 is the D1.3 anti-lysozyme antibody binding to lysozyme immobilised on the biosensor surface followed by an addition of B7-1-Fc at Point 1.
  • B7-1-Fc was replaced with Buffer at Point 2.
  • Trace 3 is the tri-specific D1.3 IgG-VLDx4 (HCLC)binding to lysozyme immobilised on the biosensor surface followed with an addition of buffer at Point 1.
  • Trace 4 is the tri-specific—D1.3 IgG-VLDx4 (HCLC) binding to lysozyme immobilised on the biosensor surface followed by an addition of
  • B7-1-Fc at Point 1.
  • B7-1-Fc was replaced with Buffer at Point 2.
  • the sensorgram demonstrates simultaneous, dual target binding to lysozyme and B7-1-Fc.
  • FIG. 13 shows Blitz® analysis demonstrating increased binding by the tri-specific relative to the bi-specific for B7-1-Fc.
  • An equivalent number of antibody, bi-specific and tri-specific molecules were captured on biotin labelled lysozyme attached to a biosensor surface followed by the addition of buffer or B7-1-Fc (at Point 1) to demonstrate increased binding capacity of the tri-specific relative to the bi-specific.
  • Trace 1 is the D1.3 anti-lysozyme antibody [D1.3 IgG] used to construct the bi-specific and tri-specific. The bound antibody is shown with Buffer only injected at Point 1.
  • Trace 2 is the D1.3 anti-lysozyme antibody [D1.3 IgG] shown with B7-1-Fc injected at Point 1 At Point 2, B7-1-Fc was replaced with Buffer.
  • Trace 3 is the bi-specific D1.3 anti-lysozyme antibody with VLDs fused to the antibody CL chains [the bi-specific—D1.3 IgG-VLDx2 (LC)]. The captured bi-specific is shown binding to B7-1-Fc which was injected at Point 1. At Point 2, B7-1-Fc was replaced with Buffer.
  • Trace 4 is the tri-specific D1.3 anti-lysozyme antibody with VLDs fused to the antibody CH and CL chains [the tri-specific—D1.3 IgG-VLDx4 (HC+LC)]. The captured bi-specific is shown binding to B7-1-Fc which was injected at Point 1. At Point 2, B7-1-Fc was replaced with Buffer.
  • FIG. 14 shows a series of SPR binding sensorgrams that have been overlaid showing initial binding of the bi-specific [IgG VLDx2 (HC)] to streptavidin captured biotin labelled lysozyme followed by secondary binding to a concentration series of B7-1-Fc (50, 25, 12.5, 6.25, 3.125, 1.56 and 0 ⁇ g/ml).
  • the bi-specific has B7-1 binding VLDs fused to the D1.3 antibody [D1.3 IgG] heavy chains.
  • FIG. 15 shows a series of SPR binding sensorgrams that have been overlaid showing initial binding of the bi-specific [IgG VLDx2 (LC)] to streptavidin captured biotin labelled lysozyme followed by secondary binding to a concentration series of B7-1-Fc (50, 25, 12.5, 6.25, 3.125, 1.56 and 0 ⁇ g/ml).
  • the bi-specific has B7-1 binding VLDs fused to the D1.3 antibody [D1.3 IgG] light chains.
  • FIG. 16 shows a series of SPR binding sensorgrams that have been overlaid showing initial binding of the tri-specific [IgG VLDx4 (HC+LC)] to streptavidin captured biotin labelled lysozyme followed by secondary binding to a concentration series of B7-1-Fc (50, 25, 12.5, 6.25, 3.125, 1.56 and 0 ⁇ g/ml).
  • the tri-specific has B7-1 binding VLDs fused to both the D1.3 antibody [D1.3 IgG] heavy and light chains.
  • FIG. 17 shows overlapped SPR binding sensorgrams showing the bi-specific [Fab-VLDx1 (HC)] binding to lysozyme followed by simultaneous binding of a concentration series of B7-1-Fc (at 25, 12.5, 6.25, 3.125, 1.56 ⁇ g/ml).
  • the bi-specific has a B7-1 binding VLD fused to the D1.3 Fab [D1.3 Fab] heavy chain.
  • FIG. 18 shows overlapped SPR binding sensorgrams showing the bi-specific [Fab-VLDx1 (LC)] binding to lysozyme followed by simultaneous binding of a concentration series of B7-1-Fc (at 25, 12.5, 6.25, 3.125, 1.56 ⁇ g/ml).
  • the bi-specific has a B7-1 binding VLD fused to the D1.3 Fab [D1.3 Fab] light chain.
  • FIG. 19 shows overlapped SPR binding sensorgrams showing the tri-specific [Fab-VLDx2(HC+LC)] binding to lysozyme followed by simultaneous binding of a concentration series of B7-1-Fc (at 25, 12.5, 6.25, 3.125, 1.56 ⁇ g/ml).
  • the tri-specific has B7-1 binding VLDs fused to both the D1.3 Fab [D1.3 Fab] heavy and light chains.
  • FIG. 20 shows the binding stoichiometry determined as a percentage of R MAX (maximal capacity) determined by SPR analysis for the bi-specific and tri-specific antibody-VLD molecules binding to B7-1-Fc.
  • FIG. 21 shows the binding stoichiometry determined as a percentage of R MAX determined by SPR analysis for the bi-specific and tri-specific Fab-VLD molecules binding to B7-1-Fc.
  • FIG. 22 shows a series of SPR binding sensorgrams that have been overlaid demonstrating initial binding of the tri-specific [IgG VLDx4 (Scl-HC)(B7-LC)] to streptavidin captured biotin labelled lysozyme followed by sequential and simultaneous binding to B7-1-Fc and sclerostin.
  • the tri-specific has sclerostin (Scl) binding VLDs fused to the D1.3 antibody [D1.3 IgG] heavy chains and B7-1 binding VLD's fused to the light chains.
  • the B7-1-Fc only trace is a sensorgram of the tri-specific showing binding to lysozyme immobilised on the biosensor surface followed by the addition of B7-1-Fc.
  • the sensorgram demonstrates simultaneous, dual target binding to lysozyme and B7-1-Fc.
  • the Sclerostin only trace is a sensorgram of the tri-specific showing binding to lysozyme immobilised on the biosensor surface followed by the addition of sclerostin.
  • the sensorgram demonstrates simultaneous, dual target binding to lysozyme and sclerostin.
  • the B7-1-Fc and Sclerostin trace is a sensorgram of the tri-specific showing binding to lysozyme immobilised on the biosensor surface followed by the addition of B7-1-Fc, and then followed by the addition of sclerostin.
  • the sensorgram demonstrates simultaneous, trio target binding to lysozyme and B7-1-Fc and sclerostin.
  • Tri-specific injected Point at which the IgG VLDx4 (Scl-HC)(B7-LC) is added to the sensor surface.
  • the trace shows the IgG VLDx4 (Scl-HC)(B7-LC) binding to lysozyme immobilised on the biosensor surface.
  • Buffer injected 1 Point at which the injection of IgG VLDx4 (Scl-HC)(B7-LC) is stopped and replaced with buffer.
  • the trace shows the dissociation of the IgG VLDx4 (Scl-HC)(B7-LC) from the lysozyme immobilised on the biosensor surface
  • B7-1-Fc injected Point at which the second analyte B7-1-Fc is added.
  • the trace shows B7-1-Fc binding to the IgG VLDx4 (Scl-HC)(B7-LC) that is still bound to the lysozyme immobilised on the biosensor surface.
  • Buffer injected 2 Point at which the injection of B7-1-Fc is stopped and replaced with buffer.
  • the trace shows the dissociation of B7-1-Fc from IgG VLDx4 (Scl-HC)(B7-LC) still attached to the lysozyme immobilised on the biosensor surface
  • Sclerostin injected Point at which the third analyte sclerostin is added.
  • the trace shows sclerostin binding to the IgG VLDx4 (Scl-HC)(B7-LC) that is still bound to the lysozyme immobilised on the biosensor surface while IgG VLDx4 (Scl-HC)(B7-LC) is simultaneously still binding B7-1-Fc.
  • Buffer injected 3 Point at which the injection of sclerostin is stopped and replaced with buffer.
  • the trace shows the dissociation of sclerostin from IgG VLDx4 (Scl-HC)(B7-LC) still attached to the lysozyme immobilised on the biosensor surface.
  • FIG. 23 shows Blitz® binding analysis demonstrating initial binding of the tri-specific [Fab VLDx2 (B7-HC)(Scl-LC)] to streptavidin captured biotin labelled lysozyme followed by sequential and simultaneous binding to B7-1-Fc and sclerostin.
  • the tri-specific has a sclerostin binding VLD fused to the D1.3 Fab [D1.3 Fab] light chain and a B7-1 binding VLD fused to the heavy chain.
  • the trace shows the tri-specific binding to lysozyme immobilised on the biosensor surface followed by the addition of B7-1-Fc.
  • the binding trace demonstrates simultaneous, dual target binding to lysozyme and B7-1-Fc. Sclerostin is added to demonstrate simultaneous, tri-target binding to lysozyme and B7-1-Fc and sclerostin.
  • Tri-specific Added Point at which the Fab VLDx2 (B7-I-HC)(Scl-LC) is added to the sensor surface.
  • the trace shows the Fab VLDx2 (B7-I-HC)(Scl-LC) binding to lysozyme immobilised on the biosensor surface.
  • B7-1-Fc Added Point at which B7-1-Fc is added.
  • the trace shows B7-1-Fc binding to the Fab VLDx2 (B71-HC)(Scl-LC) that is still bound to the lysozyme immobilised on the biosensor surface.
  • Sclerostin Added Point at which sclerostin is added.
  • the trace shows sclerostin binding to the Fab VLDx2 (B71-HC)(Scl-LC) that is still bound to the lysozyme immobilised on the biosensor surface while Fab VLDx2 (B71-HC)(Scl-LC) is simultaneously still binding B7-1-Fc.
  • Buffer Added Point at which sclerostin is replaced with buffer.
  • FIG. 24 shows Blitz® binding analysis demonstrating initial binding of the tri-specific [Fab VLDx2 (Scl-HC)(B7-LC)] to streptavidin captured biotin labelled lysozyme followed by sequential and simultaneous binding to B7-1-Fc and sclerostin.
  • the tri-specific has a sclerostin binding VLD fused to the D1.3 Fab [D1.3 Fab] heavy chain and a B7-1 binding VLD fused to the light chain.
  • the trace shows the tri-specific binding to lysozyme immobilised on the biosensor surface followed by the addition of B7-1-Fc.
  • the binding trace demonstrates simultaneous, dual target binding to lysozyme and B7-1-Fc. Sclerostin is added to demonstrate simultaneous, tri-target binding to lysozyme and B7-1-Fc and sclerostin.
  • Tri-specific Added Point at which the Fab VLDx2 (Scl-HC)(B7-LC) is added to the sensor surface.
  • the trace shows the Fab VLDx2 (Scl-HC)(B7-LC) binding to lysozyme immobilised on the biosensor surface.
  • B7-1-Fc Added Point at which B7-1-Fc is added.
  • the trace shows B7-1-Fc binding to the Fab VLDx2 (Scl-HC)(B7-LC) that is still bound to the lysozyme immobilised on the biosensor surface.
  • Sclerostin Added Point at which sclerostin is added.
  • the trace shows sclerostin binding to the Fab VLDx2 (Scl-HC)(B7-LC) that is still bound to the lysozyme immobilised on the biosensor surface while Fab VLDx2 (Scl-HC)(B7-LC) is simultaneously still binding B7-1-Fc.
  • Buffer Added Point at which sclerostin is replaced with buffer.
  • FIG. 25 shows a schematic of a protein (generic representation) coupled to a VLD according to one example of the disclosure.
  • the protein binds to target A.
  • a VLD is attached to the C-terminus of the protein polypeptide and binds to Target B.
  • the bi-specific can bind to both Target A and B either individually or at the same time.
  • FIG. 26 shows Western blot analysis and detection with anti-His horse radish peroxidase (HRP) of the purified human serum albumin (HAS)-VLD fusion proteins.
  • Lane 1 is HSA with the VLD fused to the C-terminus;
  • Lane 2 is HSA with the VLD fused to the N-terminus;
  • Lane 3 is HSA with VLDs fused to both the N-terminus and C-terminus.
  • FIG. 27 shows analysis using the ForteBio Blitz biosensor to demonstrate binding of the HSA-VLD fusion proteins to B7-2-Fc.
  • Trace 1 corresponds to the HSA-VLD fusion protein which as a B7-2 binding VLD attached to the C-terminus of HSA.
  • Trace 2 corresponds to the VDL-HSA-VLD construct having a B7-2 binding VLD attached to both the N and C-terminus of HSA.
  • Point 1 corresponds to the addition of buffer.
  • FIG. 28 shows analysis using the ForteBio Blitz biosensor to demonstrate binding of the HSA-VLD to CD3.
  • the trace shown corresponds to the binding of the molecule to CD3de.
  • Point 1 corresponds to the addition of buffer.
  • FIG. 29 shows analysis using the ForteBio Blitz biosensor to demonstrate binding of HSA-VLD fusion protein to anti-HSA affibody and B7-2-Fc.
  • the trace shown corresponds to the binding of the molecule to an anti-HSA affibody.
  • Points 1, 2 and 3 correspond to the addition of buffer.
  • composition of matter, group of steps or group of compositions of matter shall be taken to encompass one and a plurality (i.e. one or more) of those steps, compositions of matter, groups of steps or groups of compositions of matter.
  • variable regions and parts thereof, immunoglobulins, antibodies and fragments thereof herein may be further clarified by the discussion in Kabat Sequences of Proteins of Immunological Interest, National Institutes of Health, Bethesda, Md., 1987 and 1991, Bork et al., J Mol. Biol. 242, 309-320, 1994, Chothia and Lesk J. Mol Biol. 196:901 -917, 1987, Chothia et al. Nature 342, 877-883, 1989 and/or or Al-Lazikani et al., J Mol Biol 273, 927-948, 1997.
  • identity means the percentage of identical nucleotide or amino acid residues at corresponding positions in two or more sequences when the sequences are aligned to maximize sequence matching, i.e., taking into account gaps and insertions. Identity can be readily calculated by known methods, including but not limited to those described in Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, A. M., and Griffin, H.
  • Computer program methods to determine identity between two sequences include, but are not limited to, the GCG program package (Devereux, J., et al., Nucleic Acids Research 12(1): 387 (1984)), BLASTP, BLASTN, and FASTA (Altschul, S. F. et al., J. Molec. Biol. 215: 403-410 (1990) and Altschul et al. Nuc. Acids Res. 25: 3389-3402 (1997)).
  • the BLAST X program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S., et al., NCBI NLM NIH Bethesda, Md. 20894; Altschul, S., et al., J. Mol. Biol. 215: 403-410 (1990).
  • sequence identity means the percentage of pair-wise identical residues following alignment of the a sequence of a polypeptide of the present disclosure with a sequence in question with respect to the number of residues in the longer of these two sequence. Identity is measured by dividing the number of identical residues by the total number of residues and multiplying the product by 100. Thus the identity between two sequences will typically be expressed as a percentage.
  • immunoglobulin refers to a family of polypeptides which retain the immunoglobulin fold characteristics of antibody molecules, which contains two beta sheets and, usually, a conserved disulphide bond.
  • Ig superfamily include antibodies, T-cell receptor molecules and the like, ICAM molecules (which are involved in cell adhesion), receptor molecules such as the PDGF receptor which are involved in intracellular signalling.
  • the present invention relates to antibodies.
  • immunoglobulin-like domain refers to a beta-sandwich structural motif found in proteins of diverse function including for example, extracellular matrix proteins, muscle proteins, immune proteins, cell-surface receptors and enzymes. Ig-like domain members have been divided into various superfamilies, including for example, the immunoglobulin, fibronectin type III and cadherin superfamilies.
  • superfamilies containing the Ig-like domain structural motif include, for example, members of the PKD domain, ⁇ -galactosidase/glucuronidase domain, transglutamase two C-terminal domains, actinoxanthin-like, CuZn superoxide dismutase-like, CBD9-like, lamin NC globular tail domain, clathrin adaptor appendage domain, integrin domains, PapD-like, purple acid phosphatase N-terminal domain, superoxide reductase-like, thiol:disulfide interchange protein DsbD N-terminal domain and invasin/intimin cell adhesion fragments superfamilies.
  • Ig-like domain structural similarity is maintained between members of different superfamilies irrespective of significant sequence identity.
  • the term is intended to include Ig-like domain members within and across each superfamily. Therefore, the term “immunoglobulin-like (Ig-like) domain containing superfamily” is intended to refer to an Ig-like domain containing member polypeptide within any of these superfamilies as well as others known in the art.
  • a description of the different Ig-like domain containing superfamilies can be found, for example, in Clarke et al., Structure Fold. Des. 7: 1145-53 (1999) and within structural databases such as at the URL pdb.weizmann.ac.il/scop/data/scop.b.c.b.html.
  • antibody can include all classes, for example IgG, IgM, IgA, IgD or IgE or sub-classes e.g. IgG 1 , IgG 2 , IgG 3 , IgG 4 , IgA 1 and IgA 2 whether derived from any species naturally producing an antibody, or created by recombinant DNA technology, whether isolated from serum, B cells, hybridomas, transfectomas, yeast or bacteria or synthetically produced.
  • the term ‘antibody’ covers monoclonal antibodies, polyclonal antibodies, human antibodies, humanised antibodies, chimeric antibodies, primatised antibodies or synhumanized antibodies.
  • human antibody refers to antibodies containing sequences of human origin, except for possible non-human CDR regions and which has minimal immunogenicity in humans.
  • full-length antibody as used herein is intended to refer to an antibody in its substantially intact form, as opposed to an antigen binding fragment of an antibody. It may be isolated or recombinant. Specifically, whole antibodies include those with heavy and light chains including an Fc region.
  • the constant domains may be wild-type sequence constant domains (e.g., human wild-type sequence constant domains) or amino acid sequence variants thereof.
  • the antibody protein comprises a variable region made up of a plurality of polypeptide chains, e.g., a polypeptide comprising a light chain variable region (VL) and a polypeptide comprising a heavy chain variable region (VH).
  • An antibody also comprises constant domains, some of which can be arranged into a constant region, which includes a constant fragment or fragment crystallizable (Fc), in the case of a heavy chain.
  • a VH and a VL interact to form a Fv comprising an antigen binding region that is capable of specifically binding to one or a few closely related antigens. Binding interaction of the antibody with an antigen can be manifested as an intermolecular contact with one or more amino acid residues of a complementarity determining region (CDR).
  • CDR complementarity determining region
  • a light chain from mammals is either a ⁇ light chain or a ⁇ light chain and a heavy chain from mammals is ⁇ , ⁇ , ⁇ , ⁇ , or ⁇ .
  • Antibodies can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass.
  • the antibody may be a human, humanised, or chimeric antibody.
  • the antibody is a shark, camelid, feline or canine antibody.
  • immunoglobulin antigen-binding fragment as used herein is intended to refers to a fragment of an antibody, which fragment includes a light chain variable region and a heavy chain variable region having complementarity determining regions (CDRs).
  • CDRs complementarity determining regions
  • the term encompasses an Fab, F(ab′) 2 , Fab , scFv, di-scFv, or chemically linked F(ab′) 2 .
  • Fab is understood to refer to a region of an antibody that binds antigen and is composed of one constant and one variable domain of each of the heavy and the light chain.
  • complementary refers to immunoglobulin domains which form cognate pairs.
  • a VH and a VL domain of an antibody are complementary, two VH domains are not complementary and two VL domains are not complementary.
  • domain refers to a folded protein structure which retains its tertiary structure independently of the rest of the protein.
  • CDR or ‘complementarity determining region’ is intended to mean the non-contiguous antigen combining sites found within the variable region of both heavy and light chain polypeptides within an antibody or antibody fragment (which binds to an antigen). These particular regions have been described by Kabat et al., J. Biol. Chem. 252: 6609-6616 (1977); Kabat et al., U.S. Dept. of Health and Human Services, “Sequences of proteins of immunological interest” (1991); by Chothia et al., J. Mol. Biol. 196: 901-917 (1987); and MacCallum et al., J. Mol. Biol.
  • a “binding domain molecule” refers to a monomeric domain which has similar structural features to the variable heavy (VH) chain or variable light (VL) chain of an antibody. These similar structural features include BL (Binding Loop) sequences which are surface polypeptide loop structures or regions that function in a similar manner to the complementarity determining regions (CDRs) in antibody variable domains that bind to specific antigens.
  • the BDM scaffold consists of a framework sequence and three BL sequences contained within.
  • a BDM herein is not an antibody variable domain.
  • BDM scaffolds are described herein, including for example CTLA-4, lipocallins, fibronectin, ICOS and CD28.
  • a “BL sequence” is surface polypeptide loop structure or region that function in a similar manner to the complementarity determining regions (CDRs) in antibody variable domains that bind to specific antigens.
  • CDRs complementarity determining regions
  • Three antigen binding loop sequences (referred to herein as BL-1, BL-2 and BL-3 respectively) are present in the BDM and they sit within a scaffold sequence which provides the required three dimensional conformation of the loop sequences.
  • Native BL sequences can be replaced with one or more corresponding antibody CDRs which can be grafted onto the scaffold.
  • Diversity can be introduced into the BL sites of the BDM by randomising the amino acid sequence of the specific loops of the scaffold e.g. by introducing NNK codons followed by selection for desired binding characteristics using, for example, display technologies. This mechanism is similar to natural selection of high affinity, antigen-specific antibodies.
  • binding specificity in the context of a protein, polypeptide or peptide, refers to the ability of the protein or peptide and/or BDM to bind its respective target antigen or epitope which is dependent upon the presence of a particular structure (e.g., an antigenic determinant or epitope) on the target antigen or epitope.
  • a protein and/or BDM recognizes and binds to a specific protein structure rather than to proteins generally.
  • a protein binds to epitope “A”
  • the presence of a molecule containing epitope “A” (or free, unlabelled “A”), in a reaction containing labelled “A” and the protein will reduce the amount of labelled “A” bound to the protein.
  • the term should also be understood to include that the pharmacologically active protein or peptide and/or BDM “specifically binds” to a target antigen.
  • binding refers to mean that the pharmacologically active protein (or antigen binding domain thereof in the case of an antibody) or peptide and/or the BDM of the present disclosure reacts or associates more frequently, more rapidly, with greater duration and/or with greater affinity with a particular target antigen than it does with alternative target antigens.
  • Reference to ‘binding’ provides explicit support for the term ‘specific binding’ and vice versa.
  • the term is used to describe the affinity of a moiety (i.e. protein or BDM herein) for a given target antigen. In some circumstances, it may be desirable to have low affinity binding where toxicity may be an issue. In other circumstances it may be desirable to have high affinity binding to minimise cross-reactivity to other target antigens.
  • the binding is specific binding as defined herein.
  • binding affinity or “affinity” of a moiety of the molecule (i.e. the protein or the BDM) to a selected target can be measured.
  • affinity refers to the equilibrium constant for the reversible binding of two agents and is expressed as a dissociation constant (Kd) or equilibrium dissociation constant (KD).
  • the term ‘avidity’ refers to the resistance of a complex of two or more agents to dissociation after dilution.
  • antigen means a substance to which the pharmacologically active protein or peptide or BDM binds.
  • An antigen will typically comprise one or more antigenic epitopes which are recognised by the BDM or protein or peptide.
  • the protein antigen may be a soluble protein or membrane bound protein. Examples of soluble proteins include, but are not limited to transcription factors, antibodies, growth factors, blood proteins (e.g. albumin), or drugs (e.g. steroid, pharmaceutical drugs etc.). Types of membrane bound proteins include growth factor receptors, tumour markers, cell surface markers, or markers which mediate transport into a cell (e.g. transferrin), or Fc receptor. It typically refers to a substance which is capable of raising an immune response in vivo. It may be a polypeptide, protein, nucleic acid (e.g. DNA, RNA or a combination of DNA and RNA) or other molecule.
  • nucleic acid e.g. DNA, RNA or a combination of DNA and RNA
  • epitope As used herein, the term ‘epitope’ (syn. “antigenic determinant”) shall be understood to mean a region to which a protein (or an antigen-binding domain of an antibody or immunoglobulin antigen-binding fragment) binds or which the BDM of the present disclosure binds. Conventionally, the term refers to a structure bound by an immunoglobulin VH/VL pair. An epitope defines the minimum binding site for an antibody or antibody-like domain (e.g. BDM). This term is not necessarily limited to the specific residues or structure to which a protein and/or the BDM of the molecule makes contact.
  • this term includes a region spanning amino acids contacted by the CDRs of the antibody or immunoglobulin antigen-binding fragment or BL sequences of the BDM respectively, and 5-10 (or more) or 2-5 or 1-3 amino acids outside of this region.
  • the epitope comprises a series of discontinuous amino acids that are positioned close to one another when a polypeptide is folded and, for example, associated with another polypeptide, i.e., a ‘conformational epitope’.
  • the term includes those composed of a linear peptide sequence (i.e., “continuous”) or those composed of non-contiguous amino acid sequences (i.e., “conformational” or “discontinuous”).
  • target refers to an antigen or an epitope.
  • the target refers to a cell-surface protein e.g. receptor or a viral coat protein.
  • the target is a secreted protein.
  • the term ‘antigen binding domain’ in the context of an antibody or immunoglobulin antigen-binding fragment shall be taken to mean a region of an antibody or immunoglobulin antigen-binding fragment that is capable of specifically binding to an antigen, more particularly an epitope present on an antigen.
  • the antigen binding domain corresponds to the V H and V L . Within the V H and V L regions are the CDRs which make contact with the epitope.
  • position or “positions” as used herein means the position of an amino acid within an amino acid sequence depicted herein, typically counting from the left or 5′ end of the sequence.
  • corresponding as used herein in the context of the amino acid sequence positions of a BDM refers to the position of an amino acid by reference to the native or “wild-type” BDM sequence.
  • the positions will be the amino acids corresponding to the BLS1, and/or BLS2 and/or BLS3 respectively in the native BDM sequence.
  • native sequence is intended to refer to a sequence that has the same amino acid sequence as the corresponding polypeptide derived from nature.
  • a “native BDM” refers to that polypeptide having an amino acid sequence that is the same amino acid sequence as the corresponding polypeptide derived from nature.
  • Such native sequence polypeptide can be produced by recombinant or synthetic means.
  • protein shall be taken to include a single continuous and unbranched polypeptide chain, i.e., a series of contiguous amino acids linked by peptide bonds or a series of polypeptide chains covalently or non-covalently linked to one another (i.e., a polypeptide complex).
  • the series of polypeptide chains can be covalently linked using a suitable chemical or a disulfide bond.
  • non-covalent bonds include hydrogen bonds, ionic bonds, Van der Waals forces, and hydrophobic interactions.
  • peptide as used herein is taken to refer to a short chain (typically of about 50 amino acids or less) of amino acid monomers linked by peptide (amide) bonds.
  • isolated refers to a polypeptide, antibody, protein etc. that has been identified and separated and/or recovered from a component of its natural environment or the environment from which it has been produced. Contaminant components of its natural environment are materials that would interfere with therapeutic uses for the polypeptide, and can include, for example, enzymes, hormones, and other proteinaceous or non-proteinaceous solutes.
  • the polypeptide will be purified (1) to greater than 80%, 85%, 90%, 95%, or 99% by weight as determined by the Lowry method, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, and/or (3) to homogeneity by SDS-PAGE under reducing or non-reducing conditions using Coomassie blue or silver stain.
  • isolated polypeptide includes within its scope a polypeptide in situ within recombinant cells since at least one component of the polypeptides natural environment will not be present. Generally, isolation of the polypeptide will include at least one purification step.
  • recombinant shall be understood to mean the product of artificial genetic recombination.
  • a recombinant polypeptide also encompasses a polypeptide expressed by artificial recombinant means when it is within a cell, tissue or subject, e.g., in which it is expressed.
  • detect or “detecting” as used herein is understood both on a quantitative and a qualitative level, as well as a combination thereof. It thus includes quantitative, semi-quantitative and qualitative measurements of a molecule of interest.
  • the term ‘subject’ shall be taken to mean any animal including humans, for example a mammal. Exemplary subjects include but are not limited to humans and non-human primates. For example, the subject is a human. The term ‘subject’ is also intended to include non-human subjects such as for example, hamsters, rats, rabbits, cats, dogs and horses.
  • BDMs Binding Domain Molecules
  • the binding domain molecules (BDMs) of the present disclosure preferably contain a protein scaffold having three exposed binding loops (BLs).
  • the BLs can be altered i.e. replaced or modified by amino acid substitution to confer binding specificity of the BDM to a given target antigen.
  • the BDM scaffold of the present disclosure may be selected from the group consisting of an immunoglobulin-like (Ig-like) domain containing superfamily member, i-body, VNAR or VHH.
  • the Ig-like domain containing superfamily member may be selected from the group consisting of V-like domain (e.g. VLD) such as CTLA-4, C-set domain, a ThyOx family member polypeptide, a T cell receptor, CD2, CD4, CD8, class I MHC, class II MHC, CD1, cytokine receptor, G-CSF receptor, GM-CSF receptor, hormone receptors, growth hormone receptor, erythropoietin receptor, interferon gamma receptor, prolactin receptor, NCAM, VCAM, ICAM, N-caderin, E-caderin, fibronectin, tenascin, and I-set containing domain polypeptides or a functional fragment thereof.
  • V-like domain e.g. VLD
  • CTLA-4 C-set domain
  • ThyOx family member polypeptide e.g. T cell receptor
  • CD2, CD4, CD8 class I MHC, class II MHC, CD1, cytokine receptor, G-CSF
  • BDMs examples include lipocalin, protein A derived molecules such as Z-domain of Protein A (affibody, SpA), an affibody, adnectin (e,g, fibronectin) or Ankyrin repeat protein (DARPin).
  • protein A derived molecules such as Z-domain of Protein A (affibody, SpA)
  • an affibody e.g, fibronectin
  • DARPin Ankyrin repeat protein
  • the BDMs of the present disclosure have the advantages of being stable and modular in both the scaffold domain structures as well as in the ability to accept a broad range of heterologous binding loop sequences. Additionally, the BDM scaffold can be readily obtainable from human sources so that their immunogenicity when used as a human therapeutic is negligible. The BDM scaffolds can also be readily constructed to contain or omit naturally occurring polysaccharide chains.
  • Joinder of the heterologous binding loop sequences into the BDM scaffold can be performed by, for example, chemical, biochemical or recombinant means.
  • a BDM of the present disclosure refers to a molecule other than a human antibody as produced by a B cell.
  • a BDM molecule of the present disclosure is also intended to exclude antibody fragments greater than complementarity determining regions (CDRs). Therefore human antibody variable region fragments greater than about 50, 75, 100 or 110 amino acids are not encompassed within the term BDM.
  • a BDM does not include an antibody variable region such as dAb, VH-VH or VL-VL structures.
  • scaffold is intended to mean a supporting polypeptide framework used to organise, orient and harbour heterologous binding loops or altered amino acid sequences conferring binding specificity to a given target.
  • a scaffold can be structurally separable from the amino acid sequences conferring binding specificity.
  • the structurally separable portion of a scaffold can include a variety of different structural motifs including, for example, beta-sandwich, beta-sheet, alpha-helix, beta-barrel, coil-coiled and other polypeptide secondary and tertiary structures known in the art.
  • a scaffold of the present disclosure will also contain one or more regions that can be varied in amino acid sequence without substantially reducing the stability of the supporting framework structure.
  • An exemplary region that can be varied includes a binding loop segment that joins two strands of a beta-sandwich or beta-sheet.
  • a BDM scaffold of the present disclosure preferably exhibits less than about 50% amino acid identity to a human immunoglobulin variable heavy or light chain sequence.
  • the scaffold will exhibit, for example, amino acid sequence identity less than about 45%, about 40%, about 30%, about 20%, about 15%, or about 10% compared to a human immunoglobulin variable heavy or light chain amino acid sequence.
  • Residues of a scaffold that can be varied are referred to herein as external binding loops or binding loop sequences (designed herein as BL-1, BL-2 and BL-3 respectively). Residues conferring secondary or tertiary structural properties can be retained, modified or conserved so long as the overall structure of the scaffold is maintained. Those skilled in the art know, or can determine which residues function in structural stability of a polypeptide scaffold as well as the extent to which such residues can be modified.
  • the BDM scaffold is a V-like domain (VLD) protein.
  • VLD V-like domain
  • VLDs are typically distinguished from those of antibodies or T-cell receptors because they have no propensity to join together into Fv-type molecules. VLD are discussed in The Leucocyte Antigen Facts Book 1993, Eds Barclay et al., Academic Press, London; and in CD Antigens 1996 (1997) Immunology Today 18, 100-101, and in Arlene H Sharpe and Gordon J Freeman, (2002) Nature Reviews Immunology 2, 116-126, the entire contents of which are incorporated herein by reference.
  • VLD containing proteins such as CTLA-4 can provide an alternative framework for the development of novel binding moieties with high affinities for target molecules. Single domain V-like binding molecules derived from these binding moieties are soluble and therefore desirable.
  • suitable binding moieties containing a VLD are CTLA-4, CD28 and ICOS (Hutloff A et al, (1999) Nature 397(6716): 263-6).
  • CTLA-4 Cytotoxic T-lymphocyte associated antigen 4
  • CD28 and ICOS are involved in T-cell regulation during the immune response.
  • CTLA-4 is a 44 kDa homodimer expressed primarily and transiently on the surface of activated T-cells, where it interacts with CD80 and CD86 surface antigens on antigen presenting cells to effect regulation of the immune response (Waterhouse et al. (1996) Immunol Rev 153: 183-207, van der Merwe et al. (1997) J Exp Med 185(3): 393-403).
  • CD28 is a 44 kDa homodimer expressed predominantly on T-cells and, like CTLA-4, interacts with CD80 and CD86 surface antigens on antigen presenting cells to effect regulation of the immune response (Linsley et al. (1990) J Immunol 182(5): 2559-63). Current theory suggests that competition between CTLA-4 and CD28 for available ligands controls the level of immune response, for example, gene deletion of CTLA-4 in knock-out mice results in a massive over-proliferation of activated T-cells (Waterhouse et al. (1995) Science 270(5238): 985-8).
  • Each CTLA-4 monomeric subunit consists of an N-terminal extracellular domain, transmembrane region and C-terminal intracellular domain.
  • the extracellular domain comprises an N-terminal V-like domain (VLD; of approximately 14 kDa predicted molecular weight by homology to the immunoglobulin superfamily) and a stalk of about 10 residues connecting the VLD to the transmembrane region.
  • VLD comprises surface loops corresponding to BL-1, BL-2 and BL-3 respectively (Metzler W J et al (1997) Nat Struct Biol 4(7): 527-31) which binds to CD80 and/or CD86.
  • the sequence of human CTLA-4 has been previously determined (U.S. Pat. No. 5,434,131; 5,844,095; 5,851,795).
  • CD278 or ICOS inducible T-cell co-stimulator
  • ICOS inducible T-cell co-stimulator
  • the protein belongs to the CD28 and CTLA-4 cell surface receptor family. It forms homodimers and plays a role in signalling, immune responses and regulation of cell proliferation.
  • CTLA-4 The human sequence for CTLA-4 is available as UniProt reference P16410.
  • the extracellular domain of CTLA-4 corresponds to positions 36-161 of the sequence (wherein the CTLA-4 has a total length of 126 amino acids).
  • Amino acid residues 1-35 correspond to the signal peptide.
  • the human sequence for CD28 is available as UniProt reference P10747.
  • the extracellular domain corresponds to positions 19-152 of the sequence.
  • the human sequence for ICOS is available as UniProt reference Q9Y6W8.
  • the Ig-like VLD corresponds to positions 30-132 of the sequence.
  • the BDM is an immunoglobulin C-set domain protein, more preferably a C1-set domain protein.
  • C-set domains are classical Ig-like domains resembling the antibody constant domain and are found almost exclusively in molecules involved in the immune system, including the major histocompatibility complex (MHC) class I and II complex molecules and in various T cell receptors.
  • MHC major histocompatibility complex
  • Proteins such as basigin contain a C-set domain (Xiao-Ling Yu et al. (2008) JBC vol 283(26): 18056-18065). Further examples of C-set domains include ROR1 extracellular domain, CEA family members such as CEACAM1-8.
  • BDMs can be affinity matured using known selection and/or mutagenesis methods.
  • Affinity matured BDMs can have an affinity which is two times, five times, ten times, twenty times , thirty times or greater than the starting BDM.
  • Apparent affinities can be determined by methods such as ELISA or other technique familiar to persons skilled in the art e.g. surface plasmon resonance technique.
  • An i-body is a single domain antibody-like molecule of human origin.
  • the i-body framework resembles the single domain antibody from sharks and as a result shares the favourable biophysical and targeting properties of the shark antibody. They are described in for example, U.S. Pat. No. 7,977,071.
  • VNAR variable new antigen receptor
  • IgNAR shark immunoglobulin new antigen receptor antibody
  • VHH variable domain of heavy chain domain or nanobody refers to a single monomeric variable antibody domain derived from camelid antibodies. They are described, for example in Harmsen M M and H J De Haard (2007) Appl Microbiol Biotechnol. 77(1): 13-22.
  • the binding specificity of the BDM and pharmacologically active protein moieties of the molecule can be exploited to allow the molecule to bind to one or more different target antigens or epitopes, preferably at least two different target antigens or epitopes.
  • the protein has binding specificity for a first target antigen and the at least one BDM has binding specificity for a second target antigen.
  • the protein can have binding specificity for a first target antigen, and the BDM can have binding specificity for a second target antigen, and a further BDM (if present) can have binding specificity for a third target antigen.
  • the protein is an antibody or immunoglobulin antigen-binding fragment
  • the antibody or antigen-binding fragment can have binding specificity for a first target antigen
  • BDM or pair thereof if an BDM is present for example on each heavy chain or each light chain
  • a further BDM (or pair thereof) can have binding specificity for a third target antigen.
  • the molecule of the present disclosure may bind to at least one target antigen, at least two different target antigens, at least three different target antigens, at least four different target antigens or at least five different target antigens.
  • the molecule binds to one target antigen, two different target antigens or three different target antigens.
  • Various non-limiting examples are contemplated, including:
  • the protein or peptide binds to a first target antigen which is the same or different as the second target antigen bound by the BDM;
  • the antibody or immunoglobulin antigen-binding fragment binds to a first target antigen which is the same as the second target antigen bound by the BDM;
  • the antibody or immunoglobulin antigen-binding fragment binds to a first target antigen which is different from the second target antigen bound by the BDM;
  • the antibody or immunoglobulin antigen-binding fragment binds to a first target antigen, an BDM binds to a second target antigen which is the same as the first target antigen, and a further BDM binds to a third target antigen which is different from the first and second target antigens;
  • the antibody or immunoglobulin antigen-binding fragment binds to a first target antigen, a BDM and further BDM bind to a second and third target antigen respectively, wherein the second and third target antigens may be the same or different, but wherein the second and third target antigens are different from the first target antigen;
  • the antibody or immunoglobulin antigen-binding fragment binds to a first target antigen, a BDM binds to a second target antigen and a further BDM binds to a third target antigen wherein the first, second and third target antigens are different.
  • binding loop structures in the BDM domain e.g. CTLA-4
  • heterologous binding loop sequences for sclerostin or CD3 resulted in the production of soluble, monomeric, unglycosylated binding molecules using a bacterial expression system.
  • the V-like domains thus provide a basic framework for constructing soluble, single domain molecules wherein the binding specificity of the molecule may be engineered by modifications of the binding loop structures.
  • the framework residues of the BDM may be modified in accordance with structural features present in camelid antibodies.
  • the camel heavy chain immunoglobulins differ from conventional antibody structures by consisting of a single VH domain.
  • the method involves the application of well-known molecular evolution techniques to V-like domains derived from members of the immunoglobulin superfamily.
  • the method may involve the production of phage or ribosomal display libraries for screening large numbers of mutated V-like domains.
  • Filamentous fd-bacteriophage genomes are engineered such that the phage display, on their surface, proteins such as the Ig-like proteins (Fabs) which are encoded by the DNA that is contained within the phage (Smith, 1985; Huse et al., 1989; McCafferty et al., 1990; Hoogenboom et al., 1991). Protein molecules can be displayed on the surface of Fd bacteriophage, covalently coupled to phage coat proteins encoded by gene III, or less commonly gene VIII. Insertion of antibody genes into the gene III coat protein give expression of 3-5 recombinant protein molecules per phage, situated at the ends.
  • Fabs Ig-like proteins
  • insertion of antibody genes into gene VIII has the potential to display about 2000 copies of the recombinant protein per phage particle, however this is a multivalent system which could mask the affinity of a single displayed protein.
  • Fd phagemid vectors are also used, since they can be easily switched from the display of functional Ig-like fragments on the surface of Fd-bacteriophage to secreting soluble Ig-like fragments in E. coli .
  • Phage-displayed recombinant protein fusions with the N-terminus of the gene III coat protein are made possible by an amber codon strategically positioned between the two protein genes. In amber suppressor strains of E. coli , the resulting Ig domain-gene III fusions become anchored in the phage coat.
  • a selection process based on protein affinity can be applied to any high-affinity binding reagents such as antibodies, antigens, receptors and ligands (see, for example, Winter and Milstein, (1991) Nature 349: 293-299, the entire contents of which are incorporated herein by reference).
  • Ig-displaying phage can be affinity selected by binding to cognate binding partners covalently coupled to beads or adsorbed to plastic surfaces in a manner similar to ELISA or solid phase radioimmunoassays. While almost any plastic surface will adsorb protein antigens, some commercial products are especially formulated for this purpose, such as Nunc Immunotubes.
  • Ribosomal display libraries involve polypeptides synthesized de novo in cell-free translation systems and displayed on the surface of ribosomes for selection purposes (Hanes and Pluckthun, (1997) Proc Natl Acad Sci USA 94: 4937-4942; He and Taussig, (1997) Nucl Acids Res 25: 5132-5134).
  • the “cell-free translation system” comprises ribosomes, soluble enzymes required for protein synthesis (usually from the same cell as the ribosomes), transfer RNAs, adenosine triphosphate, guanosine triphosphate, a ribonucleoside triphosphate regenerating system (such as phosphoenol pyruvate and pyruvate kinase), and the salts and buffer required to synthesize a protein encoded by an exogenous mRNA.
  • the translation of polypeptides can be made to occur under conditions which maintain intact polysomes, i.e. where ribosomes, mRNA molecule and translated polypeptides are associated in a single complex. This effectively leads to “ribosome display” of the translated polypeptide.
  • the translated polypeptides in association with the corresponding ribosome complex, are mixed with a target molecule which is bound to a matrix (e.g. Dynabeads).
  • the target molecule may be any compound of interest (or a portion thereof) such as a DNA molecule, a protein, a receptor, a cell surface molecule, a metabolite, an antibody, a hormone or a virus.
  • the ribosomes displaying the translated polypeptides will bind the target molecule and these complexes can be selected and the mRNA re-amplified using RT-PCR.
  • binding molecules conforms to a pattern in which individual binding reagents are selected from display libraries by affinity to their cognate receptor.
  • the genes encoding these reagents are modified by any one or combination of a number of in vivo and in vitro mutation strategies and constructed as a new gene pool for display and selection of the highest affinity binding molecules.
  • the BDM moiety of the molecule is dimer of BDM monomers. Dimer formation may occur naturally or be facilitated by use of a linker. For example, where the BDM is a CTLA-4 VLD, dimerization may occur through a disulphide bond between cysteine residues (Cys 120 ) in the two stalks if these sequences are retained.
  • a linker can be used to couple BDM monomers (e.g. CTLA-4 monomers) together.
  • BDM monomers e.g. CTLA-4 monomers
  • This same principle can also be used to link a number of BDM monomers together in tandem to form a string.
  • the linker can facilitate enhanced flexibility, and/or reduce the steric hindrance between any two monomers.
  • the linker can be of natural origin.
  • linkers that can be used are those described further below, including the (Gly-Gly-Gly-Gly-Ser)n linker.
  • AU 60590/96 describes the preferred soluble form of CTLA-4 VLDs as a recombinant CTLA-4/Ig fusion protein expressed in eukaryotic cells and does not solve the aggregation problem in prokaryote expression systems.
  • EP 0757099A2 describes the use of CTLA-4 mutant molecules, for example the effect of changes on ligand binding of mutations in the BL sequence.
  • B7-1 (CD80) Protein and B7-2 (CD86) Protein
  • the B7 protein is a peripheral membrane protein found on activated antigen presenting cells (APC) that, when paired with either a CD28 or CD152 (CTLA-4) surface protein on a T-cell, can produce a co-stimulatory signal or a co-inhibitory signal to enhance or decrease the activity of a MHC-TCR signal between the APC and the T cell, respectively.
  • APC activated antigen presenting cells
  • CTL-4 CD152
  • B7 is also found on T-cells.
  • the B7 protein comprises a number of family members which include B7-1, B7-2, B7-DC, B7-H1 to B7-H7.
  • the B7-1 protein is also referred to as CD80 and binds to CD28 and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4).
  • CTLA-4 cytotoxic T-lymphocyte-associated protein 4
  • the BDM binds to B7-1 human protein. In one example the BDM binds to the B7-2 protein.
  • Sclerostin is a secreted glycoprotein with a C-terminal cysteine knot-like domain and sequence similarity to the DAN (differential screening-selected gene aberrative in neuroblastoma) family of bone morphogenic protein (BMP) antagonists. Sclerostin is produced by the osteocyte and has anti-anaebolic effects of bone formation.
  • the Uniprot reference of the human sequence is Q9BQB4.
  • the BDM binds to sclerostin human protein.
  • proteins completed in the present disclosure are those which are pharmacologically active.
  • proteins include an antibody (e.g. full-length antibody) or immunoglobulin antigen-binding fragment or non-antibody proteins as described herein.
  • the term “pharmacologically active” means a substance which is determined to have activity that affects a medical parameter or a disease state or causes activation of a cell involved in the immune response.
  • the protein may be an agonist protein, an antagonist protein or mimetic.
  • the protein may also be a therapeutic antibody.
  • mametic or “agonist” refer to proteins (or peptides) having biological activity comparable to the natural protein (e.g. EPO or G-CSF).
  • Exemplary proteins that are suitable in accordance with the present disclosure include, but are not limited to a blood clotting factor, an anticalin, a toxoid, a human serum albumin, a collagen binding protein, a TNF-alpha receptor binding protein, an integrin binding protein, a VEGF or mimetic thereof, an EPO or mimetic thereof, a C4 binding protein, a urokinase receptor antagonist, a lymphokine, a cytokine, an osteoprotegerin (OPG), or the extracellular domain of a protein selected from programmed cell death 1 protein (PD1), programmed death ligand 1 (PD-L1), NKG2D, MHC class I polypeptide related sequence A (MICA), MHC class I polypeptide related sequence B (MICB), UL16 binding protein (ULBP).
  • PD1 programmed cell death 1 protein
  • PD-L1 programmed death ligand 1
  • MICA MHC class I polypeptide related sequence A
  • MIMICB
  • Blood clotting factors are known in the art, examples include factor VIII and factor IX which are associated with haemophilia.
  • the toxoid is botulinium toxoid.
  • the toxoid may be botulinium type A or botulinium type B. Synthetic forms of botulinium toxoid are also contemplated.
  • the lymphokine is IL-2 or GM-CSF or mimetic thereof.
  • the cytokine is a G-CSF or mimetic thereof or stem cell factor or mimetic thereof.
  • the protein is coupled to an BDM which binds to human serum albumin so that the half-life of the protein is extended in vivo compared to the protein without the presence of the BDM.
  • the multi-specific molecule comprises a full length antibody.
  • the antibody is a humanised antibody.
  • the antibody is a human antibody.
  • the antibody is a chimeric antibody.
  • humanized antibody shall be understood to refer to a subclass of chimeric antibodies having an antigen binding site or variable region derived from an antibody from a non-human species and the remaining antibody structure based upon the structure and/or sequence of a human antibody.
  • the antigen-binding site generally comprises the complementarity determining regions (CDRs) from a non-human antibody grafted onto appropriate framework regions (FRs) in the variable regions of a human antibody and the remaining regions from a human antibody.
  • Antigen binding sites may be wild-type (i.e., identical to those of the non-human antibody) or modified by one or more amino acid substitutions.
  • FR residues of the human antibody are replaced by corresponding non-human residues.
  • the humanised antibody will comprise substantially all of at least one, and typically two variable domains in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence.
  • a humanised antibody of the present disclosure will also contain an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., (1986) Nature, 321: 522-525; Riechmann et al., (1988) Nature, 332: 323-329; and Presta, (1992) Curr. Op. Struct. Biol. 2: 593-596).
  • Fc immunoglobulin constant region
  • human antibody refers to antibodies having variable regions (e.g. VH, VL) and, optionally constant regions derived from or corresponding to sequences found in humans, e.g. in the human germline or somatic cells.
  • the ‘human’ antibodies can include amino acid residues not encoded by human sequences, e.g. mutations introduced by random or site directed mutations in vitro (in particular mutations which involve conservative substitutions or mutations in a small number of residues of the antibody, e.g. in 1, 2, 3, 4, 5 or 6 of the residues of the antibody, e.g. in 1, 2, 3, 4, 5 or 6 of the residues making up one or more of the CDRs of the antibody).
  • human antibodies do not actually need to be produced by a human, rather, they can be produced using recombinant means and/or isolated from a transgenic animal (e.g., mouse in which the endogenous immunoglobulin genes have been partially or completely inactivated) comprising nucleic acid encoding human antibody constant and/or variable regions (e.g., as described above).
  • Human antibodies can be produced using various techniques known in the art, including phage display libraries (e.g., as described in U.S. Pat. No. 5,885,793).
  • Human antibodies which recognize a selected epitope can also be generated using a technique referred to as “guided selection.”
  • a selected non-human monoclonal antibody e.g., a mouse antibody
  • is used to guide the selection of a completely human antibody recognizing the same epitope e.g., as described in U.S. Pat. No. 5,565,332.
  • Humanized immunoglobulins including humanized antibodies, have been constructed by means of genetic engineering. Most humanized immunoglobulins that have been previously described have comprised a framework that is identical to the framework of a particular human immunoglobulin chain (i.e., an acceptor or recipient), and three CDRs from a non-human (donor) immunoglobulin chain. Humanization can also include criteria by which a limited number of amino acids in the framework of a humanized immunoglobulin chain are identified and chosen to be the same as the amino acids at those positions in the donor rather than in the acceptor, in order to increase the affinity of an antibody comprising the humanized immunoglobulin chain.
  • Humanized antibodies generally have at least three potential advantages over mouse or chimeric antibodies for use in human therapy. Because the effector portion of an antibody is human, it is believed to interact better with the other parts of the human immune system (e.g., destroy the target cells more efficiently by complement-dependent cytotoxicity (CDC) or antibody-dependent cellular cytotoxicity (ADCC)). Additionally, the human immune system should not recognize the framework or constant region of the humanized antibody as foreign, and therefore the antibody response against such an injected antibody should be less than against a totally foreign mouse antibody or a partially foreign chimeric antibody. Finally, mouse antibodies are known to have a half-life in the human circulation that is much shorter than the half-life of human antibodies. Humanized antibodies can, presumably, have a half-life more similar to naturally-occurring human antibodies, allowing smaller and less frequent doses to be given.
  • CDC complement-dependent cytotoxicity
  • ADCC antibody-dependent cellular cytotoxicity
  • any full length antibody which binds to a desired target can be used in the present disclosure.
  • the full length antibody is further affinity matured before coupling to the BDM.
  • the full length immunoglobulin is a non-human immunoglobulin.
  • the immunoglobulin is a mouse, rat, hamster, cat, dog, horse or cow immunoglobulin.
  • polyclonal antisera or monoclonal antibodies can be made using standard methods.
  • a mammal e.g., a mouse, hamster, or rabbit
  • an immunogenic form of the peptide that elicits an antibody response in the mammal.
  • Techniques for conferring enhanced immunogenicity on a peptide include conjugation to carriers or other techniques well known in the art.
  • the protein or peptide can be administered in the presence of adjuvant.
  • the progress of immunization can be monitored by detection of antibody titres in plasma or serum.
  • Standard ELISA or other immunoassay procedures can be used with the immunogen as antigen to assess the levels of antibodies.
  • Folio wing immunization, antisera can be obtained and, if desired, polyclonal antibodies isolated from the sera.
  • the antibodies can be generated in cell culture, in phage, or in various animals, including but not limited to cows, rabbits, goats, mice, rats, hamsters, guinea pigs, sheep, dogs, cats, monkeys, chimpanzees, apes. Therefore, an antibody useful in the present disclosure is typically a mammalian antibody. Phage techniques can be used to isolate an initial antibody or to generate variants with altered specificity or avidity characteristics. Such techniques are routine and well known in the art.
  • the antibody is one produced by recombinant means known in the art.
  • a recombinant antibody can be produced by transfecting a host cell with a vector comprising a DNA sequence encoding the antibody.
  • One or more vectors can be used to transfect the DNA sequence expressing at least one VL and one VH region in the host cell.
  • Exemplary descriptions of recombinant means of antibody generation and production include: Delves, Antibody Production: Essential Techniques (Wiley, 1997); Shephard, et al., Monoclonal Antibodies (Oxford University Press, 2000); and Goding, Monoclonal Antibodies: Principles and Practice (Academic Press, 1993).
  • cysteine residue(s) may be introduced into the Fc region, thereby allowing interchain disulphide bond formation in this region.
  • the antibody thus generated can have improved internalisation capability and/or increased complement mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., (1992) J. Exp Med., 176: 1191-1195 and Shopes, (1992) J. Immunol., 148: 2918-2922.
  • Antibody fragments comprise a portion of an intact antibody and can include the antigen binding or variable region of an intact antibody.
  • antibody fragments suitable for use in the present disclosure include Fab, F(ab′) 2 , Fab′, scFv, di-scFv, or chemically linked F(ab′) 2 .
  • the antibody fragment is an Fab.
  • An Fv refers to antibody fragment which contain a complete antigen-recognition and binding site. This region consists of a dimer of one heavy and one light chain variable domain in tight, non-covalent association. It is in this configuration that the three CDRs of each variable domain interact to define an antigen-binding site on the surface of the VH-VL dimer. Collectively, the six CDRs confer antigen-binding specificity to the antibody fragment.
  • An Fab fragment contains an Fv and also contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain.
  • Fab fragments differ from Fab′ fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain include one or more cysteines from the antibody hinge region.
  • F(ab′) 2 fragments are produced as pairs of Fab′ fragments which have hinge cysteines between them.
  • Chemically linked F(ab′) 2 are bi-specific molecules formed by pairing two different Fab′ fragments together each of which has a different binding specificity.
  • Techniques for generating bi-specific antibodies from antibody fragments have been described in the literature. For example, bi-specific antibodies can be prepared using chemical linkage.
  • Brennan et al (1985) Science 229: 81 describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab′) 2 fragments. These fragments are reduced in the presence of dithiol complexing agent sodium arsenite to stabilise vicinal dithiols and prevent intermolecular disulphide formation.
  • the Fab′ fragments generated are then converted to thionitrobenzoate (TNB) derivatives.
  • One of the Fab′-TNB derivatives is then reconverted to the Fab′-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab′-TNB derivative to form the bi-specific antibody.
  • the present disclosure also provides methods for making a multi-specific molecule of the present disclosure.
  • Expression of the molecules can be in prokaryotic or eukaryotic cells.
  • Prokaryotes most frequently are represented by various strains of bacteria.
  • the bacteria may be a gram positive or a gram negative.
  • gram-negative bacteria such as E. coli are preferred.
  • Other microbial strains may also be used.
  • Sequences encoding the molecules can be cloned into vectors designed for expressing foreign sequence in prokaryotic cells such as E. coli .
  • These vectors can include commonly used prokaryotic control sequences which are defined herein to include promoters for transcription initiation, optionally with an operator, along with ribosome binding site sequences, include such commonly used promoters as the beta-lactamase (penicillinase) and lactose (lac) promoter systems (Chang, et al., (1977) Nature 198: 1056), the tryptophan (trp) promoter system (Goeddel, et al., (1980) Nucleic Acids Res. 8: 4057) and the lambda derived PL promoter and N-gene ribosome binding site (Shimatake, et al., (1981) Nature 292: 128).
  • promoters as the beta-lactamase (penicillinase) and lactose (lac) promoter
  • Such expression vectors will also include origins of replication and selectable markers, such as a beta-lactamase or neomycin phosphotransferase gene conferring resistance to antibiotics, so that the vectors can replicate in bacteria and cells carrying the plasmids can be selected for when grown in the presence of antibiotics, such as ampicillin or kanamycin.
  • origins of replication such as a beta-lactamase or neomycin phosphotransferase gene conferring resistance to antibiotics, so that the vectors can replicate in bacteria and cells carrying the plasmids can be selected for when grown in the presence of antibiotics, such as ampicillin or kanamycin.
  • Suitable host cells include bacteria, mammalian cells, yeast and baculovirus systems.
  • Suitable host cells include bacteria, mammalian cells, yeast and baculovirus systems.
  • Mammalian cell lines available in the art for expression of a heterologous polypeptide include Chinese hamster ovary cells, HeLa cells, Human Embryonic Kidney Cells, baby hamster kidney cells, NSO mouse melanoma cells and many others.
  • Suitable hosts will be selected by consideration of, e.g., their compatibility with the chosen vector, their secretion characteristics, their ability to fold proteins correctly, and their fermentation requirements, as well as the toxicity to the host of the product encoded by the DNA sequences to be expressed, and the ease of purification of the expression products.
  • nucleic acid is inserted operably linked to a promoter in an expression construct or expression vector for further cloning (amplification of the DNA) or for expression in a cell-free system or in cells.
  • Vectors can be plasmids, viral e.g. ‘phage, or phagemid, as appropriate.
  • nucleic acid sequence encoding an antibody light chain sequence, heavy chain sequence, and a linker sequence as described herein and an BDM sequence is cloned by standard methods into a suitable vector.
  • the BDM will be cloned at a C-terminal end of the antibody light chain sequence. In some examples, the BDM will be cloned at a C-terminal end of the antibody heavy chain sequence. In some examples, the BDM will be cloned at an N-terminal end of the antibody light chain sequence. In some examples, the BDM will be cloned at a N-terminal end of the antibody heavy chain sequence. In some examples, BDMs will be cloned at both an N-terminal and a C-terminal ends of the antibody light chain sequence. In some examples, BDMs will be cloned at both an N-terminal and a C-terminal ends of the antibody heavy chain sequence.
  • BDMs will be cloned at both an N-terminal and a C-terminal ends of both the antibody light chain sequence and heavy chain sequence.
  • the nucleic acid sequence encoding the antibody heavy or light chain and BDM is provided in one vector and the other antibody chain is provided on another vector.
  • a nucleic acid sequence encoding an antibody light chain sequence, a linker sequence and a BDM sequence are cloned into one vector and a nucleic acid sequence encoding an antibody heavy chain sequence, a linker sequence and a BDM sequence are cloned into another vector.
  • a bicistronic vector may be used whereby both antibody light and heavy chains are expressed on the same vector.
  • the heavy and light chain coding sequences may reside on a single vector, for example in tow expression cassettes in the same vector.
  • Nucleic acid sequences encoding the molecules can also be inserted into a vector designed for expressing foreign sequences in a eukaryotic host.
  • the regulatory elements of the vector can vary according to the particular eukaryotic host.
  • Useful expression vectors can consist of segments of chromosomal, non-chromosomal and synthetic DNA sequences.
  • Suitable vectors include derivatives of SV40 and known bacterial plasmids, e.g., E. coli plasmids col El, Pcr1, Pbr322, Pmb9 and their derivatives, plasmids such as RP4; phage DNAs, e.g., the numerous derivatives of phage A, e.g., NM989, and other phage DNA, e.g., M13 and filamentous single stranded phage DNA; yeast plasmids such as the 2u plasmid or derivatives thereof; vectors useful in eukaryotic cells, such as vectors useful in insect or mammalian cells; vectors derived from combinations of plasmids and phage DNAs, such as plasmids that have been modified to employ phage DNA or other expression control sequences; and the like.
  • Nucleic acid sequences encoding the molecules can integrate into the genome of the eukaryotic host cell and replicate as the host genome replicates.
  • the vector carrying the nucleic acid sequences can contain origins of replication allowing for extrachromosomal replication.
  • promoter is to be taken in its broadest context and includes the transcriptional regulatory sequences of a genomic gene, including the TATA box or initiator element, which is required for accurate transcription initiation, with or without additional regulatory elements (e.g., upstream activating sequences, transcription factor binding sites, enhancers and silencers) that alter expression of a nucleic acid, e.g., in response to a developmental and/or external stimulus, or in a tissue specific manner.
  • promoter is also used to describe a recombinant, synthetic or fusion nucleic acid, or derivative which confers, activates or enhances the expression of a nucleic acid to which it is operably linked.
  • Exemplary promoters can contain additional copies of one or more specific regulatory elements to further enhance expression and/or alter the spatial expression and/or temporal expression of said nucleic acid.
  • operably linked to means positioning a promoter relative to a nucleic acid such that expression of the nucleic acid is controlled by the promoter.
  • the vector components generally include, but are not limited to, one or more of the following: a signal sequence, a sequence encoding a protein (e.g., derived from the information provided herein), an enhancer element, a promoter, polyadenylation sequences and a transcription termination sequence.
  • a signal sequence e.g., a sequence encoding a protein (e.g., derived from the information provided herein)
  • an enhancer element e.g., derived from the information provided herein
  • a promoter e.g., derived from the information provided herein
  • polyadenylation sequences e.g., a promoter
  • a transcription termination sequence e.g., a transcription termination sequence.
  • Exemplary signal sequences include prokaryotic secretion signals (e.g., pelB, alkaline phosphatase, penicillinase, Ipp, or heat-stable enterotoxin II), yeast secretion signals (e.g., invertase leader, a factor leader, or acid phosphatase leader) or mammalian secretion signals (e.g., herpes simplex gD signal).
  • prokaryotic secretion signals e.g., pelB, alkaline phosphatase, penicillinase, Ipp, or heat-stable enterotoxin II
  • yeast secretion signals e.g., invertase leader, a factor leader, or acid phosphatase leader
  • mammalian secretion signals e.g., herpes simplex gD signal.
  • Exemplary promoters active in mammalian cells include cytomegalovirus immediate early promoter (CMV-IE), human elongation factor 1- ⁇ promoter (EF1), small nuclear RNA promoters (U1a and U1b), ⁇ -myosin heavy chain promoter, Simian virus 40 promoter (SV40), Rous sarcoma virus promoter (RSV), Adenovirus major late promoter, ⁇ -actin promoter; hybrid regulatory element comprising a CMV enhancer/ ⁇ -actin promoter or an immunoglobulin promoter or active fragment thereof.
  • CMV-IE cytomegalovirus immediate early promoter
  • EF1 human elongation factor 1- ⁇ promoter
  • U1a and U1b small nuclear RNA promoters
  • ⁇ -myosin heavy chain promoter ⁇ -myosin heavy chain promoter
  • Simian virus 40 promoter SV40
  • Rous sarcoma virus promoter RSV
  • Adenovirus major late promoter ⁇ -
  • Examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells sub-cloned for growth in suspension culture; baby hamster kidney cells (BHK, ATCC CCL 10); or Chinese hamster ovary cells (CHO).
  • COS-7 monkey kidney CV1 line transformed by SV40
  • human embryonic kidney line (293 or 293 cells sub-cloned for growth in suspension culture
  • baby hamster kidney cells BHK, ATCC CCL 10
  • Chinese hamster ovary cells CHO
  • Means for introducing the isolated nucleic acid or expression construct comprising same into a host cell for expression are known to those skilled in the art. The technique used for a given cell depends on the known successful techniques. Means for introducing recombinant DNA into cells include microinjection, transfection mediated by DEAE-dextran, transfection mediated by liposomes such as by using lipofectamine (Gibco, Md., USA) and/or cellfectin (Gibco, Md., USA), PEG-mediated DNA uptake, retroviral transduction, electroporation and microparticle bombardment such as by using DNA-coated tungsten or gold particles (Agracetus Inc., Wis., USA) amongst others.
  • the introduction can be followed by causing or allowing expression from the nucleic acid, e.g. by culturing host cells under conditions for expression.
  • the present disclosure also provides a method which comprises using a construct as stated above in an expression system in order to express the antibody or immunoglobulin antigen-binding fragment chains and BDM.
  • the present disclosure also provides a recombinant host cell which comprises one or more nucleic acid sequences described herein.
  • the host cells used to produce the protein may be cultured in a variety of media, depending on the cell type used.
  • Commercially available media such as Ham's FIO (Sigma), Minimal Essential Medium ((MEM), (Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium ((DMEM), Sigma) are suitable for culturing mammalian cells.
  • Media for culturing other cell types discussed herein are known in the art.
  • a wide variety of host/expression vector combinations can be employed in expressing the nucleic acid sequences of this disclosure.
  • Useful expression vectors can consist of segments of chromosomal, non- chromosomal and synthetic DNA sequences.
  • Suitable vectors include derivatives of SV40 and known bacterial plasmids, e.g., E. coli plasmids col El, Perl, Pbr322, Pmb9 and their derivatives, plasmids such as RP4; phage DNAs, e.g., the numerous derivatives of phage ⁇ e.g., NM989, and other phage DNA, e.g., M13 and filamentous single stranded phage DNA; yeast plasmids such as the 2u plasmid or derivatives thereof; vectors useful in eukaryotic cells, such as vectors useful in insect or mammalian cells; vectors derived from combinations of plasmids and phage DNAs, such as plasmids that have been modified to employ phage DNA or other expression control sequences; and the like Also provided here
  • useful expression control sequences include, for example, the early or late promoters of SV40, CMV, vaccinia, polyoma or adenovirus, the lac system, the tip system, the TAC system, the TRC system, the LTR system, the major operator and promoter regions of phage A, the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid phosphatase (e.g., Pho5), the promoters of the yeast -mating factors, and other sequences known to control the expression of genes of prokaryotic or eukaryotic cells or their viruses, and various combinations thereof.
  • the present disclosure provides an isolated polynucleotide (nucleic acid) encoding a polypeptide as described herein, vectors containing such polynucleotides, and host cells and expression systems for transcribing and translating such polynucleotides into polypeptides.
  • the present disclosure also provides constructs in the form of plasmids, vectors, transcription or expression cassettes as described elsewhere herein which comprise at least one polynucleotide as above.
  • the present disclosure also provides a host cell containing one or more polynucleotides as disclosed herein.
  • nucleic acid molecules and vectors described herein can be provided isolated and/or purified, e.g., from their natural environment, in substantially pure or homogeneous form, or, in the case of nucleic acid, free or substantially free of nucleic acid or genes origin other than the sequence encoding a polypeptide with the required function.
  • Nucleic acid can comprise DNA or RNA and can be wholly or partially synthetic.
  • yeast vectors For expressing the nucleic acid sequences in Saccharomyces cerevisiae , the origin of replication from the endogenous yeast plasmid, the 2 ⁇ circle can be used. (Broach, (1983) Meth. Enz. 101: 307). Alternatively, sequences from the yeast genome capable of promoting autonomous replication can be used (see, for example, Stinchcomb et al., (1979) Nature 282: 39); Tschemper et al., (1980) Gene 10: 157; and Clarke et al., (1983) Meth. Enz. 101: 300). Transcriptional control sequences for yeast vectors include promoters for the synthesis of glycolytic enzymes (Hess et al., (1968) J. Adv.
  • Additional promoters known in the art include the CMV promoter provided in the CDM8 vector (Toyama and Okayama, (1990) FEBS 268: 217-221); the promoter for 3-phosphoglycerate kinase (Hitzeman et al., (1980) J. Biol. Chem. 255: 2073), and those for other glycolytic enzymes.
  • polypeptides can be detected by methods known in the art.
  • the molecules can be detected by Coomassie staining SDS-PAGE gels and immunoblotting using antibodies that bind either the antibody, immunoglobulin antigen-binding fragment or BDM.
  • Protein recovery can be performed using standard protein purification means, e.g., affinity chromatography or ion-exchange chromatography, to yield substantially pure product (R. Scopes in: “Protein Purification, Principles and Practice”, Third Edition, Springer-Verlag (1994)).
  • the present disclosure also provides a method of producing a multi-specific molecule of the present disclosure which method comprises the steps of:
  • step (iii) culturing the host cells of step (b) under conditions conducive to the secretion of the proteins from the host cell into the culture media;
  • step (iv) recovering the secreted proteins of step (iii).
  • the method comprises:
  • a nucleic acid encoding a polypeptide of the present disclosure can be prepared synthetically in addition to, or rather than, cloned.
  • the nucleic acid can be designed with the appropriate codons for the polypeptide moieties (e.g. immunoglobulin and BDM). In general, one will select preferred codons for an intended host if the sequence will be used for expression. In general one will select preferred codons for the intended host if the sequence will be used for expression.
  • the complete polynucleotide can be assembled from overlapping oligonucleotides prepared by standard methods and assembled into a complete coding sequence.
  • supernatants from such expression systems can be first concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit.
  • a protease inhibitor such as PMSF may be included in any of the foregoing steps to inhibit proteolysis and antibiotics may be included to prevent the growth of adventitious contaminants.
  • supernatants can be filtered and/or separated from cells expressing the polypeptide, e.g., using continuous centrifugation.
  • polypeptides prepared from the host cells can be purified using, for example, ion exchange, hydroxyapatite chromatography, hydrophobic interaction chromatography, gel electrophoresis, dialysis, affinity chromatography (e.g., protein A affinity chromatography or protein G chromatography), or any combination of the foregoing.
  • affinity chromatography e.g., protein A affinity chromatography or protein G chromatography
  • a polypeptide of the present disclosure is fused to a heterologous amino acid sequence, without affecting the biological activity (i.e. binding to its targets), such as for instance a signal sequence or an affinity tag.
  • a polypeptide can be modified to include an affinity tag to facilitate purification or detection, e.g., a poly-histidine tag, e.g., a hexa-histidine tag, or an influenza virus hemagglutinin (HA) tag, or a Simian Virus 5 (V5) tag, or a FLAG tag, or a glutathione S-transferase (GST) tag.
  • an affinity tag to facilitate purification or detection
  • a poly-histidine tag e.g., a hexa-histidine tag, or an influenza virus hemagglutinin (HA) tag, or a Simian Virus 5 (V5) tag, or a FLAG tag, or a glutathione S-transferase (GST) tag.
  • affinity tag to facilitate purification or detection
  • a poly-histidine tag e.g., a hexa-histidine tag, or an influenza virus hemagglutin
  • a polypeptide comprising a hexa-his tag is purified by contacting a sample comprising the polypeptide with nickel-nitrilotriacetic acid (Ni-NTA) that specifically binds a hexa-his tag immobilized on a solid or semi-solid support, washing the sample to remove unbound protein, and subsequently eluting the bound protein.
  • Ni-NTA nickel-nitrilotriacetic acid
  • Coupling of the pharmacologically active protein or peptide and at least BDM according to present disclosure can be prepared using chemical linkage (Brennan et al (1985) Science 229: 81) or chemical coupling (Shalaby et al (1992) J Exp Med 175: 217-225) or gene fusion.
  • fusion or linkage between a protein (e.g. antibody) and a BDM may be achieved by conventional covalent or ionic bonds, protein fusions, or heterobifunctional cross-linkers, e.g., carbodiimide, glutaraldehyde, and the like.
  • Conventional inert linker sequences e.g. peptide linkers
  • the design of such linkers is well known to those of skill in the art and is described for example in U.S. Pat. No. 8,580,922; 5,525,491; and 6,165,476.
  • cross-linking agents can be used for covalent conjugation of proteins.
  • cross-linking agents include protein A, carbodiimide, N-succinimidyl-S-acetyl-thioacetate (SATA), 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB), o-phenylenedimaleimide (oPDM), N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), and sulfosuccinimidyl 4-(N-maleimidomethyl) cyclohaxane-1-carboxylate (sulfo- SMCC) (see e.g., Karpovsky el al.
  • the linker can facilitate enhanced flexibility, and/or reduce steric hindrance between any two proteins.
  • the linker can be of natural origin, such as a sequence determined to exist in random coil between two domains of a protein.
  • An exemplary linker sequence is the linker found between the C-terminal and N-terminal domains of the RNA polymerase alpha subunit.
  • Other examples of naturally occurring linkers include linkers found in the 1Cl and LexA proteins.
  • the amino acid sequence may be varied based on the preferred characteristics of the linker as determined empirically or as revealed by modelling. Considerations in choosing a linker include flexibility of the linker, charge of the linker, and presence of some amino acids of the linker in the naturally-occurring subunits.
  • the linker can also be designed such that residues in the linker contact DNA, thereby influencing binding affinity or specificity, or to interact with other proteins. In some cases, particularly when it is necessary to span a longer distance between subunits or when the domains must be held in a particular configuration, the linker may optionally contain an additional folded domain.
  • linker In some examples it is preferable that the design of a linker involve an arrangement of domains which requires the linker to span a relatively short distance, preferably less than about 10 Angstroms ( ⁇ ). However, in certain embodiments, linkers span a distance of up to about 50 ⁇ or more.
  • peptide linker refers to a short peptide fragment that connects or couples the protein and the BDM moieties of the polypeptide of the multi-specific molecule.
  • the linker is preferably made up of amino acids linked together by peptide bonds.
  • the peptide linker can comprise small amino acid residues or hydrophilic amino acid residues (e.g. glycine, serine, threonine, proline, aspartic acid, asparagine, etc).
  • the peptide linkers are peptides with an amino acid sequence with a length of at least 5 amino acids, or with a length of about 5 to about 100 amino acids, or with a length of about 10 to 50 amino acids, or a length of about 10 to 15 amino acids.
  • the linker is made up of a majority of amino acids that are sterically unhindered such as glycine and alanine.
  • the linkers are polyclycines, polyalanines or polyserines.
  • the short peptide linkers may comprise repeat units to increase the linker length.
  • the linker comprises a formula (Gly-Gly-Gly-Gly-Ser)n or comprising the formula (Ser-Gly-Gly-Gly-Gly)n Ser wherein n is a number from 3 to 6.
  • the linker comprises or consist of the sequence
  • Non-peptide linkers are also possible.
  • These alkyl linkers may be further substituted by any non-sterically hindering group such as lower alkyl (e.g. C 1 -C 6 ), lower acyl, halogen (e.g. Cl, Br), CN, NH 2 , phenyl.
  • An exemplary non-peptide linker is a PEG linker having a molecular weight of 100 to 5000 kD, preferably 100 to 500 kD.
  • linkers which are suitable for use include GSTVAAPS, TVAAPSGS or GSTVAAPSGS or multiples of such linkers.
  • the linker is GS.
  • the protein (or peptide) and BDM moieties of the present disclosure can be assayed by various means according to known methods.
  • assays may include functional assays e.g. cell killing assays, cAMP or calcium flux assays or binding assays e.g. ELISA or competition assays.
  • the type of functional assays employed will depend on the targets to which the protein or peptide and BDM moieties of the polypeptide bind.
  • Half-life assays may also be employed. Such methods are known in the art. Two methods commonly used to determine a protein's half-life are the radioactive pulse-chase analysis and the cycloheximide chase (Zhou P (2004) Methods Mol. Biol. 284: 67-77.
  • Binding of epitopes can be measured by conventional by conventional antigen binding assays, such as ELISA, by fluorescence based techniques, including FRET, or by techniques such as surface plasmon resonance which measure the mass of molecules.
  • Specific binding of an antigen binding protein (e.g. BDM) to an antigen or epitope can be determined by suitable assay, including, for example, Scatchard analysis and/or competitive binding assays such as radioimmunoassay (RIA), enzyme immunoassays such as ELISA and sandwich competition assays.
  • suitable assay including, for example, Scatchard analysis and/or competitive binding assays such as radioimmunoassay (RIA), enzyme immunoassays such as ELISA and sandwich competition assays.
  • Competition assays such as surface plasmon resonance assays can be used to determine whether a BDM which has been engineered to bind a particular target is capable of doing so.
  • a BDM can be engineered to bind to the stem cell factor receptor (CSFR or c-kit receptor) and tested for its ability to compete with binding of the natural ligand (c-kit).
  • CSFR stem cell factor receptor
  • c-kit natural ligand
  • In vitro competition assays for determining the ability of a modified BDM to compete for binding to a target as well as determining the dissociation constant (K D ) are known in the art.
  • the binding affinity or dissociation constant (K D ) of the interaction between the protein or BDM moiety of the polypeptide and its respective target can be measured by a number of methods known in the art. Such methods include, but are not limited to, fluorescence titration, competition ELISA, calorimetric methods, such as isothermal titration calorimetry (ITC) and surface plasmon resonance (BIAcore) or Bio-layer interferometry (e.g. Blitz system (ForteBio).
  • ITC isothermal titration calorimetry
  • BIOAcore surface plasmon resonance
  • Bio-layer interferometry e.g. Blitz system (ForteBio).
  • a preferred surface plasmon resonance assay is BIAcore which is known in the art.
  • binding moieties have K D values in the low micromolar (10 ⁇ 6 ) to nanomolar (10 ⁇ 7 to 10 ⁇ 9 ) range.
  • High affinity binding moieties are generally considered to be in the low nanomolar range (10 ⁇ 9 ) with very high affinity binding moieties being in the picomolar (10 ⁇ 12 ) range.
  • the complex formation between the respective moiety and its target is influenced by many different factors such as the concentrations of the respective binding partners, the presence of competitors. pH and the ionic strength of the buffer system used, and the experimental method used for determination of the K D (for example, fluorescence titration, competition ELISA or surface plasmon resonance) or even the mathematical algorithm which is used for evaluation of the experimental data.
  • the K D values may vary within a certain experimental range, depending on the method and experimental setup that is used for determining the affinity of a particular immunoglobulin or BDM for a given target. This means that there may be a slight deviation in the measured KD values or a tolerance range depending on whether the KD value was determined by surface plasmon resonance (Biacore), by competition ELISA or by “direct ELISA”.
  • the KD value is determined by using surface plasmon resonance assays, e.g., using BIAcore surface plasmon resonance (BIAcore, Inc., Piscataway, N.J.) to an immobilised target.
  • surface plasmon resonance assays e.g., using BIAcore surface plasmon resonance (BIAcore, Inc., Piscataway, N.J.) to an immobilised target.
  • Affinity can be at least 1-fold greater, at least 2-fold greater, at least 3-fold greater, at least 4-fold greater, at least 5-fold greater, at least 6-fold greater, at least 7-fold greater, at least 8-fold greater, at least 9-fold greater, at least 10-fold greater, at least 20-fold greater, at least 30-fold greater, at least 40-fold greater, at least 50-fold greater, at least 60-fold greater, at least 70-fold greater, at least 80-fold greater, at least 90-fold greater, at least 100-fold greater, or at least 1000-fold greater, or more, than the affinity of the protein or the BDM for unrelated amino acid sequences.
  • Affinity of a protein or BDM to a target e.g.
  • protein antigen can be, for example, from about 100 nanomolar (nM) to about 0.1 nM, from about 100 nM to about 1 picomolar (pM), or from about 100 nM to about 1 femtomolar (fM) or more.
  • the protein has an affinity measured by KD of about 200 nM or lower, about 100 nM or lower, about 50 nM or lower, about 25 nM or lower, about 10 nM or lower, of about 5 nM or lower, of about 1 nM or lower or of about 0.5 nM or lower.
  • the BDM has an affinity measured by KD of about 200 nM or lower, about 100 nM or lower, about 50 nM or lower, about 25 nM or lower, 10 nM or lower, of about 5 nM or lower, of about 1 nM or lower or of about 0.5 nM or lower.
  • Bio-layer interferometry is a label-free technology for measuring biomolecular interactions within the interactome. It is an optical analytical technique that analyses the interference pattern of white light reflected from two surfaces: a layer of immobilized protein on the biosensor tip, and an internal reference layer. Any change in the number of molecules bound to the biosensor tip causes a shift in the interference pattern that can be measured in real-time.
  • the binding between a ligand immobilized on the biosensor tip surface and an analyte in solution produces an increase in optical thickness at the biosensor tip, which results in a wavelength shift, ⁇ which is a direct measure of the change in thickness of the biological layer. Interactions are measured in real time, providing the ability to monitor binding specificity, rates of association and dissociation, or concentration, with precision and accuracy.
  • the target according to the present disclosure is preferably an antigen.
  • the antigen may be selected from a protein, a glycan, a lipid, a lipoprotein or nucleic acid.
  • the protein may be a human protein, non-human protein (e.g. primate, canine, feline etc.), viral protein, yeast protein, bacterial protein, algae protein, plant protein or protozoal protein.
  • the protein may be a soluble protein or membrane bound protein. Examples of soluble proteins include, but are not limited to transcription factors, antibodies, growth factors, blood proteins (e.g. albumin), or drugs (e.g. steroid, pharmaceutical drugs etc.). Types of membrane bound proteins include growth factor receptors, tumour markers, or markers which mediate transport into a cell (e.g. transferrin), or Fc receptor.
  • the nucleic acid target may be DNA, RNA or a combination of DNA and RNA.
  • the target is an epitope present on the antigen.
  • an antigen may comprise a number of unique epitopes, each of which will be recognised by a protein (e.g. antibody) or BDM.
  • the polypeptide of the present disclosure can bind to different targets.
  • the different targets are two or three different antigens. Each antigen may be present on different cells.
  • the polypeptide may bind to two or three different targets (e.g. epitopes) on the same antigen.
  • the target to which protein binds is different from the target to which the BDM binds.
  • target antigen may be a protein, peptide, a glycoprotein, a polysaccharide, a glycan, a lipid, a lipoprotein or nucleic acid.
  • Target antigens according to the present disclosure may be secreted or membrane bound.
  • Such antigens may be derived from bacterial, mammalian (human and non-human), fungal, algael, protozoal sources.
  • the protein may be a human protein, non-human protein (e.g. primate, canine, feline etc.), viral protein, yeast protein, bacterial protein, algae protein, plant protein or protozoal protein.
  • first target antigen “second target antigen” etc. being the same will be understood to mean that the pharmacologically active protein and the at least one BDM moiety bind to the same antigen but may bind to different epitopes present on the antigen.
  • first target antigen “second target antigen” etc. being different will be understood to mean that the pharmacologically active protein moiety and the at least one BDM moiety bind to different antigens and thus different epitopes present on different cells.
  • the antigen can be derived from bacteria, including but not limited to, Helicobacter pylori, Chlamydia pneumoniae, Chlamydia trachomatis, Ureaplasma urealyticum, Mycoplasma pneumoniae, Staphylococcus spp., Staphylococcus aureus, Streptococcus spp., Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus viridans, Enterococcus faecalis, Neisseria meningitidis, Neisseria gonorrhoeae, Bacillus anthracis, Salmonella spp., Salmonella typhi, Vibrio cholera, Pasteurella pestis, Pseudomonas aeruginosa, Campylobacter spp., Campylobacter jejuni, Clostridium spp., Clostridium difficile, Mycobacterium s
  • the antigen can be derived from viruses, including but not limited to, Influenza viruses, a Parainfluenza viruses, Mumps virus, Adenoviruses, Respiratory syncytial virus, Epstein-Barr virus, Rhinoviruses, Polioviruses, Coxsackieviruses, Echoviruses, Rubeola virus, Rubella virus, Varicell-zoster virus, Herpes viruses (human and animal), Herpes simplex virus, Parvoviruses (human and animal), Cytomegalovirus, Hepatitis viruses, Human papillomavirus, Alphaviruses, Flaviviruses, Bunyaviruses, Rabies virus, Arenaviruses, Filoviruses, HIV 1, HIV 2, HTLV-1, HTLV-II, FeLV, Bovine LV, FeIV, Canine distemper virus, Canine contagious hepatitis virus, Feline calicivirus, Feline rhinotracheitis virus, TGE virus (swine), and Foot
  • the target antigen may be a tumour associated antigen.
  • tumour associated antigens include, but are not limited to, MUC-1 and peptide fragments thereof, protein MZ2-E, polymorphic epithelial mucin, folate-binding protein LK26, MAGE-1 or MAGE-3 and peptide fragments thereof, Human chorionic gonadotropin (HCG) and peptide fragments thereof, Carcinoembryonic antigen (CEA) and peptide fragments thereof, Alpha fetoprotein (AFP) and peptide fragments thereof, Pancreatic oncofetal antigen and peptide fragments thereof, CA 125, 15-3,19-9, 549, 195 and peptide fragments thereof, Prostate-specific antigens (PSA) and peptide fragments thereof, Prostate-specific membrane antigen (PSMA) and peptide fragments thereof, Squamous cell carcinoma antigen (SCCA) and peptide fragments thereof, Ovarian cancer antigen (OCA) and peptide fragments thereof
  • the target antigen may be an antigen or epitope present on a cell located within the heart, blood system, lungs, intestine, stomach, rectum, prostate, thyroid, liver or oesophagus.
  • the target antigen may be an antigen or epitope present on a secreted protein. Examples of secreted proteins include, but are not limited to hormones, enzymes, toxins and anticmicrobial, peptides. Alternatively, the antigen or epitope is present on a non-membrane bound protein.
  • the molecule can bind selectively to cells that express two or more of the different target antigens of the multi-specific molecule over cells that express only one of the target antigens.
  • Such cell selectivity can be achieved by titrating the binding affinity of each moiety (e.g. protein or BDM) on the bi-specific or tri-specific such that each individual moiety bound insufficiently to its target to enable fluorescence activated cell sorting (FACS) or immunofluoresnce labelling or cell killing or cells expressing that target in the absence of the other targets bound by the bi-specific or tri-specific but wherein the combination of the weak binding moieties prompt sufficient avidity of the bi-specific or tri-specific to enable selective binding of cells co-expressing the relevant target molecules compared to cells expressing only one such target, such that selective FACS sorting, immunofluorescent labelling or cell killing could be achieved.
  • FACS fluorescence activated cell sorting
  • the multi-specific molecules of the present disclosure can be used as a composition when combined with a pharmaceutically acceptable carrier or excipient. Such pharmaceutical compositions are useful for administration to a subject in vivo.
  • Pharmaceutically acceptable carriers are physiologically acceptable to the administered patient and retain the therapeutic properties of the molecule with which it is administered.
  • Pharmaceutically-acceptable carrier and their formulations are generally described in, for example, Remington' pharmaceutical Sciences 18 th edn. Ed. A Gennaro, Mack Publishing Co., Easton Pa. 1990).
  • One exemplary carrier is physiological saline.
  • pharmaceutically acceptable carrier means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the polypeptides from the administration site of one organ or potion of the body, to another organ, or portion of the body.
  • Each carrier must be acceptable in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.
  • the pharmaceutically acceptable excipient may include a preservative or cyropreservative.
  • compositions can be formulated to be compatible with a particular route of administration, systemic or local.
  • composition described herein can be administered orally, parenterally, by inhalation spray, adsorption, absorption, topically, rectally, nasally, bucally, vaginally, intraventricularly, via an implanted reservoir in dosage formulations containing conventional non-toxic pharmaceutically-acceptable carriers, or by any other convenient dosage form.
  • parenteral as used herein includes subcutaneous, intravenous, intramuscular, intraperitoneal, intrathecal, intraventricular, intrasternal, and intracranial injection or infusion techniques.
  • Methods for preparing a molecule into a suitable form for administration to a subject are known in the art and include, for example, methods as described in Remington's Pharmaceutical Sciences (18th ed., Mack Publishing Co., Easton, Pa., 1990) and U.S. Pharmacopeia: National Formulary (Mack Publishing Company, Easton, Pa., 1984).
  • compositions of this disclosure are particularly useful for parenteral administration, such as intravenous administration or administration into a body cavity or lumen of an organ or joint.
  • the compositions for administration will commonly comprise a solution of polypeptide dissolved in a pharmaceutically acceptable carrier, for example an aqueous carrier.
  • a pharmaceutically acceptable carrier for example an aqueous carrier.
  • aqueous carriers can be used, e.g., buffered saline and the like.
  • the compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, for example, sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like.
  • concentration of proteins of the present disclosure in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight and the like in accordance with the particular mode of administration selected and the patient's needs.
  • exemplary carriers include water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin.
  • Non-aqueous vehicles such as mixed oils and ethyl oleate may also be used.
  • Liposomes may also be used as carriers.
  • the vehicles may contain minor amounts of additives that enhance isotonicity and chemical stability, e.g., buffers, preservatives or additives.
  • polypeptides of the present disclosure will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically/prophylactically effective.
  • Formulations are easily administered in a variety of dosage forms, such as the type of injectable solutions described above, but other pharmaceutically acceptable forms are also contemplated, e.g., tablets, pills, capsules or other solids for oral administration, suppositories, pessaries, nasal solutions or sprays, aerosols, inhalants, liposomal forms and the like.
  • Pharmaceutical “slow release” capsules or compositions may also be used. Slow release formulations are generally designed to give a constant drug level over an extended period and may be used to deliver compounds of the present disclosure.
  • suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS).
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof. Fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • Antibacterial and antifungal agents include, for example, parabens, chlorobutanol, phenol, ascorbic acid and thimerosal.
  • Isotonic agents for example, sugars, polyalcohols such as manitol, sorbitol, and sodium chloride may be included in the composition.
  • the resulting solutions can be packaged for use as is, or lyophilized; the lyophilized preparation can later be combined with a sterile solution prior to administration.
  • Pharmaceutically acceptable carriers can contain a compound that stabilizes, increases or delays absorption or clearance.
  • Such compounds include, for example, carbohydrates, such as glucose, sucrose, or dextrans; low molecular weight proteins; compositions that reduce the clearance or hydrolysis of peptides; or excipients or other stabilizers and/or buffers.
  • Agents that delay absorption include, for example, aluminum monostearate and gelatin.
  • Detergents can also be used to stabilize or to increase or decrease the absorption of the pharmaceutical composition, including liposomal carriers.
  • the compound can be complexed with a composition to render it resistant to acidic and enzymatic hydrolysis, or the compound can be complexed in an appropriately resistant carrier such as a liposome.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations are known to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to cells or tissues using antibodies or viral coat proteins) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known in the art, for example, as described in U.S. Pat. Nos.
  • Molecules of the present disclosure can be incorporated within micelles (see, e.g., Suntres (1994) J. Pharm. Pharmacol. 46: 23 28; Woodle (1992) Pharm. Res. 9:2 60 265).
  • the molecule can be attached to the surface of the lipid monolayer or bilayer.
  • molecules can be attached to hydrazide-PEG-(distearoylphosphatidy-I) ethanolamine-containing liposomes (see, e.g., Zalipsky (1995) Bioconjug. Chem. 6: 705 708).
  • lipid membrane such as a planar lipid membrane or the cell membrane of an intact cell, e.g., a red blood cell
  • Liposomal and lipid-containing formulations can be delivered by any means, including, for example, intravenous, transdermal (see, e.g., Vutla (1996) J. Pharm. Sci. 85:5 8), transmucosal, or oral administration.
  • compositions of the present disclosure can be combined with other therapeutic moieties or imaging/diagnostic moieties as provided herein.
  • Therapeutic moieties and/or imaging moieties can be provided as a separate composition, or as a conjugated moiety.
  • Linkers can be included for conjugated moieties as needed and have been described elsewhere herein.
  • the molecules disclosed herein may also be formulated as immunoliposomes.
  • Liposomes containing the polypeptide are prepared by methods known in the art, such as described in Epstein et al., Proc. Natl. Acad. Sci. USA, 82: 3688 (1985); Hwang et al., Proc. Natl Acad. Sci. USA, 77: 4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Pat. No. 5,013,556.
  • Formulations for in vivo administration are sterile. Sterilization can be readily accomplished via filtration through sterile filtration membranes.
  • compositions of the present disclosure can be administered with other therapeutic agents, e.g. chemotherapeutic agents.
  • Chemotherapeutic agents are known in the art and include cytotoxic and cytostatic drugs. Non-limiting examples include paclitaxel, cisplatin, methotrexate, doxorubicin, fludarabine etc,. Other therapeutic agents are contemplated depending on the condition to be treated.
  • One embodiment of the present disclosure contemplates the use of any of the pharmaceutical compositions of the present disclosure to make a medicament for treating a disorder.
  • Medicaments can be packaged in a suitable pharmaceutical package with appropriate labels wherein the label is for the indication of treating a disorder in a subject.
  • the present disclosure provides a molecule described herein labelled with an agent.
  • the agent is an imaging/detectable moiety.
  • the agent is a therapeutic moiety.
  • label or “labelled” is intended to encompass direct labelling of the protein (e.g. antibody) or BDM by coupling coupling (i.e. physically linking) a detectable substance to said protein or BDM, as well as indirect labelling by reactivity with another reagent that is directly labelled.
  • label also includes covalent or non-covalent coupling.
  • the molecule can be labelled with a toxin, a radionuclide, iron-related compound, a dye, an imaging agent or a fluorescent label or a chemotherapeutic agent.
  • the molecule can be labelled with detectable label, such as a radionuclide, iron-related compound, a dye, an imaging agent or a fluorescent agent for immunodetection of target antigens.
  • detectable label such as a radionuclide, iron-related compound, a dye, an imaging agent or a fluorescent agent for immunodetection of target antigens.
  • Radiolabels include, for example, 32 P, 33 P, 43 K, 52 Fe, 57 Co, 64 Cu, 67 Ga, 67 Cu, 68 Ga, 71 Ge, 75 Br, 76 Br, 77 Br, 77 As, 81 Rb/ 81 MKr, 87 MSr, 90 Y, 97 Ru, 99 Tc, 100 Pd, 101 Rh, 103 Pb, 105 Rh, 109 Pd, 111 Ag, 111 In, 113 In, 119 Sb, 121 Sn, 123 I, 125 I, 127 Cs, 128 Ba, 129 Cs, 131 I, 131 Cs, 143Pr, 153 Sm, 161 Tb, 166 Ho, 169 Eu, 177 Lu, 186 Re, 188 Re, 189Re, 191Os, 193Pt, 194 Ir, 197 Hg, 199 Au, 203 Pb, 211 At, 212 Pb, 212 Bi and 213 Bi.
  • radionuclides are available for the production of radioconjugated proteins. Examples include, but are not limited to, low energy radioactive nuclei (e.g., suitable for diagnostic purposes), such as 130 C, 15 N , 2 H, 125 I, 123 I, 99 Tc, 43 K, 52 Fe, 67 Ga, 68 Ga, 111 In and the like.
  • the radionuclide is a gamma, photon, or positron-emitting radionuclide with a half-life suitable to permit activity or detection after the elapsed time between administration and localization to the imaging site.
  • the present disclosure also encompasses high energy radioactive nuclei (e.g., for therapeutic purposes), such as 125 I, 131 I, 123 I, 111 In, 105 Rn, 153 Sm, 67 Cu, 67 Ga, 166 Ho, 177 Lu, 186 Re and 188 Re.
  • high energy radioactive nuclei e.g., for therapeutic purposes
  • isotopes typically produce high energy ⁇ - or ⁇ -particles which have a short path length.
  • Such radionuclides kill cells to which they are in close proximity, for example neoplastic cells to which the conjugate has attached or has entered. They have little or no effect on non-localized cells and are essentially non-immunogenic.
  • high-energy isotopes may be generated by thermal irradiation of an otherwise stable isotope, for example as in boron neutron-capture therapy (Guan et al., 1998).
  • isotopes which may be suitable are described in Carter. (2001) Nature Reviews Cancer 1, 118-29, Goldmacher et al. (2011) Therapeutic Delivery 2; 397-416, Payne (2003) Cancer Cell 3, 207-212, Schrama et al, (2006) Nature Rev. Drug Discov. 5, 147-159, Reichert et al. (2007) Nature Reviews Drug Discovery 6; 349-356.
  • a toxin includes any agent that is detrimental to (e.g., kills) cells. Additional techniques relevant to the preparation of antibody immunotoxin conjugates are provided in for instance in U.S. Pat. No. 5,194,594 and may be utilised in the present disclosure.
  • Non-limiting examples of toxins include, for example, diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa ), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, tricothecenes, Clostridium perfringens phospholipase C (PLC), bovine pancreatic ribonuclease (BPR), antiviral protein (PAP), abrin, cobra venom factor (CVF), gelonin (GEL), saporin (SAP)
  • Non-limiting examples of iron-related compounds include, for example, magnetic iron-oxide particles, ferric or ferrous particles, Fe203 and Fe304.
  • Iron- related compounds and methods of labelling polypeptides, proteins and peptides can be found, for example, in U.S. Pat. Nos. 4,101,435 and 4,452,773, and U.S. published applications 20020064502 and 20020136693, all of which are hereby incorporated by reference in their entirety.
  • the molecule can be labelled to a cytotoxin or other cell proliferation inhibiting compound, in order to localize delivery of that agent to a tumor cell.
  • the agent can be selected from the group consisting agents, enzyme inhibitors, proliferation inhibitors, lytic agents, DNA or RNA synthesis inhibitors, membrane permeability modifiers, DNA metabolites, dichloroethylsulfide derivatives, protein production inhibitors, ribosome inhibitors, inducers of apoptosis, and neurotoxins.
  • a molecule as described herein comprises one or more detectable markers to facilitate detection and/or isolation.
  • the polypeptide comprises a fluorescent label such as, for example, fluorescein (FITC), 5,6-carboxymethyl fluorescein, Texas red, nitrobenz-2-oxa-1,3-diazol-4-yl (NBD), coumarin, dansyl chloride, rhodamine, 4′-6-diamidino-2-phenylinodole (DAPI), and the cyanine dyes Cy3, Cy3.5, Cy5, Cy5.5 and Cy7, fluorescein (5-carboxyfluorescein-N-hydroxysuccinimide ester), rhodamine (5,6-tetramethyl rhodamine).
  • FITC fluorescein
  • NBD nitrobenz-2-oxa-1,3-diazol-4-yl
  • DAPI nitrobenz-2-oxa-1,3-diazol-4-yl
  • the absorption and emission maxima, respectively, for these fluors are: FITC (490 nm; 520 nm), Cy3 (554 nm; 568 nm), Cy3.5 (581 nm; 588 nm), Cy5 (652 nm: 672 nm), Cy5.5 (682 nm; 703 nm) and Cy7 (755 nm; 778 nm).
  • the molecule can be coupled with an agent useful in imaging tumours.
  • agents include: metals; metal chelators; lanthanides; lanthanide chelators; radiometals; radiometal chelators; positron-emitting nuclei; microbubbles (for ultrasound); liposomes; molecules microencapsulated in liposomes or nanosphere; monocrystalline iron oxide nanocompounds; magnetic resonance imaging contrast agents; light absorbing, reflecting and/or scattering agents; colloidal particles; fluorophores, such as near-infrared fluorophores.
  • such secondary functionality/moiety will be relatively large, e.g., at least 25 amu in size, and in many instances can be at least 50,100 or 250 amu in size.
  • the secondary functionality is a chelate moiety for chelating a metal, e.g., a chelator for a radiometal or paramagnetic ion. In additional examples, it is a chelator for a radionuclide useful for radiotherapy or imaging procedures.
  • the molecule may be labelled with, for example, a magnetic or paramagnetic compound, such as, iron, steel, nickel, cobalt, rare earth materials, neodymium-iron-boron, ferrous-chromium-cobalt, nickel-ferrous, cobalt- platinum, or strontium ferrite.
  • a magnetic or paramagnetic compound such as, iron, steel, nickel, cobalt, rare earth materials, neodymium-iron-boron, ferrous-chromium-cobalt, nickel-ferrous, cobalt- platinum, or strontium ferrite.
  • the molecule is conjugated to a “receptor” (such as streptavidin) for utilization in cell pretargeting wherein the conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a “ligand” (e.g., avidin) that is conjugated to a therapeutic agent (e.g., a radionucleotide).
  • a receptor such as streptavidin
  • a “ligand” e.g., avidin
  • a therapeutic agent e.g., a radionucleotide
  • Exemplary therapeutic agents include, but are not limited to an anti-angiogenic agent, an anti-neovascularization and/or other vascularization agent, an anti-proliferative agent, a pro-apoptotic agent, a chemotherapeutic agent, anti-mitotic agents (eg anti-mitotic agent Auristatin, (MMAF/MMAE as per Angew. Chem. Int. Ed. 2014, 53, 1-6) or a therapeutic nucleic acid.
  • an anti-angiogenic agent an anti-neovascularization and/or other vascularization agent
  • an anti-proliferative agent e.g., a pro-apoptotic agent
  • a chemotherapeutic agent eg anti-mitotic agent Auristatin, (MMAF/MMAE as per Angew. Chem. Int. Ed. 2014, 53, 1-6
  • a therapeutic nucleic acid eg anti-mitotic agent Auristatin, (MMAF/MMAE as per Angew. Chem
  • Chemotherapeutics useful as agents herein include cytotoxic and cytostatic drugs. Chemotherapeutics may include those which have other effects on cells such as reversal of the transformed state to a differentiated state or those which inhibit cell replication. Examples of known cytotoxic agents useful in the present invention are listed, for example, in Goodman et al., “The Pharmacological Basis of Therapeutics,” Sixth Edition, A. B. Gilman et al., eds./Macmillan Publishing Co. New York, 1980.
  • taxanes such as paclitaxel and docetaxel
  • nitrogen such as mechlorethamine, melphalan, uracil mustard and chlorambucil
  • ethylenimine derivatives such as thiotepa
  • alkyl sulfonates such as busulfan
  • nitrosoureas such as lomustine, semustine and streptozocin
  • triazenes such as dacarbazine
  • folic acid analogs such as methotrexate
  • pyrimidine analogs such as fluorouracil, cytarabine and azaribine
  • purine analogs such as mercaptopurine and thioguanine
  • vinca alkaloids such as vinblastine and vincristine
  • antibiotics such as dactinomycin, daunorubicin, doxorubicin, and mitomycin
  • enzymes platinum coordination complexes, such as cisplatin
  • substituted urea such as
  • multi-specific molecule as described herein is further conjugated or linked to another protein (e.g. Human Serum Albumin or HSA).
  • another protein e.g. Human Serum Albumin or HSA
  • the non-antibody protein is HSA.
  • the molecule may also be conjugated or linked to a therapeutic agent or a liposome (e.g. drug containing liposome).
  • Drugs that interfere with protein synthesis can also be used; such drugs are known to those skilled in the art and include puromycin, cycloheximide, and ribonuclease.
  • the molecules of the present disclosure can be modified to contain additional nonproteinaceous moieties that are known in the art and readily available.
  • the moieties suitable for derivatization of the protein are physiologically acceptable polymer, e.g., a water soluble polymer.
  • physiologically acceptable polymer e.g., a water soluble polymer.
  • water soluble polymers include, but are not limited to, polyethylene glycol (PEG), polyvinyl alcohol (PVA), or propropylene glycol (PPG).
  • the molecules of the present disclosure can be used for affinity purification or detection of desired antigens bearing an epitope to which the protein (or peptide) and/or BDM binds.
  • the present disclosure also provides a method for detecting a target to which either or both of the protein and BDM moieties of the polypeptide bind.
  • Such methods may for example, employ the use of detectable labels as described above.
  • different labels could be utilised for the protein and the BDM to identify whether the target bound is that bound by the protein or the BDM.
  • a variety of formats can be employed to determine whether a sample contains a target (e.g. protein) that binds to the protein or peptide and/or BDM.
  • a target e.g. protein
  • formats include, but are not limited to, enzyme immunoassay (EIA), radioimmunoassay (RIA), Western blot analysis and enzyme linked immunoabsorbant assay (ELISA).
  • the polypeptide in one format, can be used in methods such as Western blots or immunofluorescence techniques to detect a target.
  • the polypeptide or target antigen to which the protein (or peptide) or BDM binds may be immobilised on a solid support.
  • the multi-specific molecule may be bound to a solid support.
  • Suitable solid phase supports or carriers include any support capable of binding an antigen (i.e. target) or an immunoglobulin or BDM.
  • Well-known supports or carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, gabbros, and magnetite.
  • One skilled in the art will know many other suitable carriers for binding the protein, BDM or target antigen, and will be able to adapt such support for use with the present disclosure.
  • target protein can be run on a polyacrylamide gel electrophoresis and immobilized onto a solid phase support such as nitrocellulose.
  • the support can then be washed with suitable buffers followed by treatment with the detectably labelled polypeptide.
  • the solid phase support can then be washed with the buffer a second time to remove unbound polypeptide.
  • the amount of bound label on the solid support can then be detected by conventional means.
  • the molecules of the present disclosure can be used as medicaments.
  • a factor VIII protein can be coupled to a VLD that binds to human serum albumin so that the half-life of the protein is increased. This has obvious advantages in terms of less frequent dosing for subjects with haemophilia.
  • the molecules according to the present disclosure provide advantages over therapeutics based on bi-specific antibodies.
  • a simple and efficient approach for improving one or more characteristics of an antibody, e.g. poorly therapeutic antibody is to attach one or more single binding domain molecules (BDM) that bind to specific therapeutic targets to an antibody or an immunoglobulin antigen-binding fragment which has specificity to a target of interest.
  • BDM single binding domain molecules
  • bi-specific approach simple and highly efficient bi-specific antibody generation; the approach is applicable to any antibody sequence; the parent antibody retains its original binding sites and specificity; the parent antibody retains its avidity; the parent antibody retains its original structure and function and antibody-mediated effector functions are retained for select applications; antibody pharmacokinetics including serum half-life are retained; the bi-specific product integrates seamlessly into existing IgG production processes such as manufacturing, purification, formulation and all other processes based on standard IgG processes.
  • bi-specifics based on antibody Fab fragments will also be desirable due to their smaller molecular weight, shorter half-life in the blood stream and an improved molecular weight to binding site ratio relative to whole antibodies.
  • the neutralisation of toxic substances which have been traditionally treated with whole antibodies can be more effectively treated with Fabs. Due to the relatively large molecular weight of an antibody (150 kDa) as compared to the toxic substance (typically less than 1 kDa), a large quantity of antibody is required to bind stoichiometrically to the toxin. Bi-specific or tri-specific Fabs described herein can be used at lower dose due to the multiple binding sites offered by the bi-specific or tri-specific. The small size of Fabs relative to antibodies sees the toxic substance-Fab complexes quickly excreted via the kidneys. Again, an efficient and simple approach for generating Fab-based bi-specifics is to attach BDM's that bind to specific targets to an existing Fab which has specificity to a target of interest.
  • kits comprising a multi-specific molecule described herein, together with instructions for use.
  • the kit can contain further preparations of solutions to reconstitute the preparations.
  • the instructions may be on ‘printed matter’, e.g., on paper or cardboard within or affixed to the kit, or on a label affixed to the kit or packaging material, or attached to a vial or tube containing a component of the kit.
  • kits can further include any of the other moieties provided herein such as, for example, a chemotherapeutic agent.
  • kits can further include the components for an assay provided herein, for example an ELISA assay.
  • the kit may further include a label specifying, for example a product description, mode of administration and indication of treatment.
  • the label or packaging insert can include appropriate written instructions.
  • CTLA-4 BDMs were obtained from a library (Geneart).
  • the gene library 1696327 was assembled using synthetic degenerated oligonucleotides with the objective of containing different substitutions in the DNA sequence corresponding to the binding loop regions.
  • CTLA-4 sequence used in these examples comprise a C-terminal modification of the native sequence wherein the native sequence PEPCPDSDGSTG is replaced with PEPSPDSN. These sequence does not contain the C-terminus Cys residue which allows the BDM to remain in monomeric form.
  • Nucleic acid constructs encoding anti-lysozyme IgG1 heavy chain sequence fused to the B7-1 binding CTLA-4 V-like domain sequence designated D1.3 IgG-VLDx2 (HC)
  • anti-lysozyme IgG kappa light chain sequence fused to B7-1 binding V-like domain sequence designated D1.3 IgG-VLDx2 (LC)
  • the VLD was coupled to the antibody heavy (H) or light (L) chain respectively through a Gly-Ser linker sequence. All DNA constructs were verified by restriction analysis and DNA sequencing and tested for expression of recombinant protein by standard and well-understood techniques.
  • VLD B7-1 binding V-like domain
  • Linker sequence (SEQ ID NO: 16) SGGGGSGGGGSGGGGS Linker sequence (SEQ ID NO: 17) SGGGGSGGGGSGGGGSGGGGS Anti-Lysozyme IgG1 heavy chain sequence used in antibody-VLD fusions (SEQ ID NO: 18) EVKLQESGPGLVAPSQSLSITCTVSGFSLTGYGVNWVRQPPGKGLEWLGMIWGDGNTDYNS ALKSRLSISKDNSKSQVFLKMNSLHTDDTARYYCARERDYRLDYWGQGTTVTVSSASTKGPS VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT VPSSSLGTQTYICNVNHKPSNTKVDKKVEPPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL
  • Anti-Lysozyme IgG kappa light chain (SEQ ID NO: 20) DIELTQSPASLSASVGETVTITCRASGNIHNYLAWYQQKQGKSPQLLVYYTTTLADGVPSRFSG SGSGTQYSLKINSLQPEDFGSYYCQHFWSTPRTFGGGTKLELKRTVAAPSVFIFPPSDEQLKS GTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKH KVYACEVTHQGLSSPVTKSFNRGEC Anti-Lysozyme IgG kappa light chain coupled to B7-1 binding VLD with a 21 aa Gly-Ser linker (designated D1.3 IgG-VLDx2 (LC)) (SEQ ID NO: 21) DIELTQSPASLSASVGETVTITCRASGNIHNYLAWYQQKQGKSPQLLVYYTTTLADGVPSRFSG
  • Anti-lysozyme Fab heavy chain coupled to B7.1 binding VLD with 21 aa Gly-Ser linker designated D1.3 Fab-VLDx1 (HC) (SEQ ID NO: 23) EVKLQESGPGLVAPSQSLSITCTVSGFSLTGYGVNWVRQPPGKGLEWLGMIWGDGNTDYNS ALKSRLSISKDNSKSQVFLKMNSLHTDDTARYYCARERDYRLDYWGQGTTVTVSSASTKGPS VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT VPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCSGGGGSGGGGSGGGGSGGGGSKAMHVA QPAVVLASSRGIASFVCEY ASPGKYTE VRVTVLRQADSQVTEVCAATY MTGNEL TFLDDSICT GTSSGNQVNLTIQGLRAMDTGLYICKV ELMYPPPYY LGIGNG
  • Anti-lysozyme Fab Heavy chain (with C-terminal His6 and myc tags) (SEQ ID NO: 24) EVKLQESGPGLVAPSQSLSITCTVSGFSLTGYGVNWVRQPPGKGLEWLGMIWGDGNTDYNS ALKSRLSISKDNSKSQVFLKMNSLHTDDTARYYCARERDYRLDYWGQGTTVTVSSASTKGPS VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT VPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCAAAGLGGHHHHHHGAAEQKLISEEDL
  • FIG. 2 shows a schematic of the antibody-VLD bi-specific molecule according to one example created by coupling of a target specific VLD (e.g. that bind to Target B) to the terminal end of each constant heavy (CH3) chain sequence of the anti-Lysozyme IgG1 antibody heavy chain [D1.3 IgG-VLDx2 (HC)].
  • the antibody molecule binds to target A via the antibody heavy and light chain variable regions and to target B via the VLD on the heavy chain.
  • FIG. 3 shows a schematic of the antibody-VLD bi-specific molecule according to one example created by coupling a target specific VLD (e.g. that bind to Target B) to the terminal end of each constant light (CL) chain sequence of the anti-Lysozyme IgG1 antibody light chain
  • a target specific VLD e.g. that bind to Target B
  • CL constant light
  • the molecule binds to target A via the antibody heavy and light chain variable regions and to target B via the VLD on the light chain.
  • FIG. 4 shows a schematic of the antibody-VLD tri-specific molecule according to one example created by coupling of a target specific VLD (e.g. that bind to Target B) to both the heavy and light chains D1.3 IgG-VLDx4 (LC+HC) where a VLD is coupled to the terminal CL sequence and also to the terminal end of the heavy CH3 sequence.
  • the molecule binds to target A via the antibody heavy and light chain variable regions, to target B via the VLD on the light chain and to target C via the same VLD or a different VLD to that which binds target B.
  • the tri-specific can bind to Target A, B and C either individually or at the same time or in a combination of the three targets (e.g. Target and B or Target A and C or Target B and C).
  • FIG. 5 shows a schematic of the bi-specific Fab-VLD molecule (D1.3 Fab-VLDx1 (HC)) according to one example the disclosure.
  • the bi-specific is created by a fusion of a target specific VLD (e.g. in this example the VLD is specific for Target B) to the terminal end of the constant region (CH1) sequence of a Fab that binds to Target A (e.g. in this example the Fab is specific for Target A).
  • the bi-specific can bind to both Target A and B either individually or at the same time.
  • FIG. 6 shows a schematic of the bi-specific Fab-VLD molecule (D1.3 Fab-VLDx1 (LC)) according to one example of the disclosure.
  • the bi-specific is created by a fusion of a target specific VLD (e.g. in this example the VLD is specific for Target B) to the terminal end of the CL sequence of a Fab that binds to Target A (e.g. in this example the Fab is specific for Target A).
  • the bi-specific can bind to both Target A and B either individually or at the same time.
  • FIG. 7 shows a schematic of the tri-specific Fab-VLD molecule (D1.3 Fab-VLDx2 (LC+HC)) according to the disclosure.
  • the tri-specific is created by a fusion of a target specific VLD (e.g. in this example the VLD is specific for Target B) to the terminal end of the Fab CL sequence and a fusion of a second target specific VLD (e.g. in this example the VLD is specific for Target C) to the terminal end of the Fab CH3 sequence that binds to Target A (e.g. in this example the Fab is specific for Target A).
  • the tri-specific can bind to Target A and B and C either individually or at the same time or in a combination of the three targets (e.g. Target A and B or Target A and C or Target B and C).
  • Vector transformation of bacteria was performed according to standard techniques using 2 ng of DNA using the electroporation competent cell line (e.g. ElectroTen-Blue cells, Stratagene Cat #200159).
  • electroporation competent cell line e.g. ElectroTen-Blue cells, Stratagene Cat #200159.
  • the antibody or Fab binds to lysozyme and the VLD binds to B7.1.
  • ProsepA purification was used for purification of the bi-specific and tri-specific molecules.
  • the ProsepA column was equilibrated with 5 column volumes of PBS/Tris (2 mM Tris, pH 8). Transfected cell supernatant containing the bi-specific molecule at pH 8 was loaded onto the column and the column washed with 10 column volumes of PBS, 2 mM Tris, pH 8. The protein was eluted with 0.1 M Glycine pH 3. The eluted protein fraction was neutralized to -pH 7 with 1 M Tris, pH 8. and dialysed according to standard methods.
  • Protein expression levels of the variants were determined by SDS PAGE. Values were obtained from 30m1 expression cultures which were purified via affinity chromatography (not shown).
  • D1.3 Fab expression of parent D1.3 Fab, and its bi-specifics and tri-specific variants which were expressed in a non-optimised standard Expi293 expression system were analysed by SDS PAGE under non-reducing and reducing conditions. Values were obtained from 30 ml expression cultures which were purified via affinity chromatography.
  • the parent Fab is D1.3 Fab
  • the bi-specific are D1.3 Fab-VLDx1 (HC) which is the D1.3 Fab plus a VLD fused to the terminal end of the CH sequence of the D1.3 Fab
  • D1.3 Fab-VLDx1 (CL) which is the D1.3 Fab plus a VLD fused to the terminal end of the CL sequence of the D1.3 Fab.
  • D1.3 Fab-VLDx2 (HC+LC) which is the D1.3 Fab plus VLDs fused to both the terminal end of the CH sequence and CL sequence of the D1.3 Fab. Results are shown in FIG. 8 under non-reducing conditions. Results are known in FIG. 9 under reducing conditions. Analysis indicated that appropriate heavy and light chain fusions were at the size ranges expected.
  • the binding properties of the purified bi-specific and tri-specific molecules were characterised using the ForteBio Blitz biosensor using standard chemistry and reagents.
  • Affinity chromatography purified antibodies, antibody-VLD bi-specific and antibody-VLD tri-specific molecules were used with commercially available Lysozyme (Sigma Aldrich cat# L4919) and B7-1-Fc (R&D Systems Cat # 140-B1).
  • a streptavidin capturing surface SA Sensor ForteBio cat# 18-5019, or Sensor Chip SA, GE Cat# BR-1000-32 was used to capture biotin labelled lysozyme.
  • the antibody, antibody-VLD bi-specific and antibody-VLD tri-specific molecules were passed over the target captured on the biosensor surface to generate a binding sensorgram (i.e. first specificity). Over the same target, during the dissociation phase, B7-1-Fc was passed over the already bound antibody, antibody-VLD bi-specific and antibody-VLD tri-specific molecules (i.e. the second specificity) to demonstrate the second binding interaction.
  • FIG. 10 shows preliminary analysis using the ForteBio Blitz biosensor to demonstrate binding of the bi-specific [IgG VLDx2 (HC)] to streptavidin captured biotin labelled lysozyme followed by secondary binding to B7.1-Fc.
  • the bi-specific has B7-1 binding VLDs coupled to the D1.3 antibody [D1.3 IgG] heavy chains.
  • Trace 1 is a sensorgram of the D1.3 anti-lysozyme antibody [D1.3 IgG] used to construct the bi-specific.
  • the antibody is shown binding to lysozyme immobilised on the biosensor surface followed by an addition of Buffer at Point 1.
  • Trace 2 is a sensorgram of the D1.3 anti-lysozyme antibody [D1.3 IgG] used to construct the bi-specific.
  • the antibody is shown binding to lysozyme immobilised on the biosensor surface followed by an addition of B7-1-Fc at Point 1.
  • B7-1-Fc was replaced with Buffer at Point 2.
  • Trace 3 is a sensorgram of the bi-specific D1.3 anti-lysozyme antibody with VLDs coupled to the antibody constant heavy (CH) chains [the bi-specific—D1.3 IgG-VLDx2 (HC)].
  • the bi-specific is shown binding to lysozyme immobilised on the biosensor surface followed with an addition of buffer at Point 1.
  • Trace 4 is a sensorgram of the bi-specific D1.3 anti-lysozyme antibody with VLDs coupled to the antibody CH chains [the bi-specific—D1.3 IgG-VLDx2 (HC)].
  • the bi-specific is shown binding to lysozyme immobilised on the biosensor surface followed by an addition of B7-1-Fc at Point 1.
  • B7-1-Fc was replaced with Buffer at Point 2.
  • FIG. 11 shows preliminary analysis using the ForteBio Blitz biosensor to demonstrate binding of the bi-specific [IgG VLDx2 (LC)] to streptavidin captured biotin labelled lysozyme followed by secondary binding to B7-1-Fc.
  • the bi-specific has B7-1 binding VLDs coupled to the D1.3 antibody [D1.3 IgG] light chains.
  • Trace 1 is a sensorgram of the D1.3 anti-lysozyme antibody [D1.3 IgG] used to construct the bi-specific.
  • the antibody is shown binding to lysozyme immobilised on the biosensor surface followed by an addition of Buffer at Point 1.
  • Trace 2 is a sensorgram of the D1.3 anti-lysozyme antibody [D1.3 IgG] used to construct the bi-specific.
  • the antibody is shown binding to lysozyme immobilised on the biosensor surface followed by an addition of B7-1-Fc at Point 1.
  • B7-1-Fc was replaced with Buffer at Point 2.
  • Trace 3 is a sensorgram of the bi-specific D1.3 anti-lysozyme antibody with VLDs coupled to the antibody constant light (CL) chains [the bi-specific—D1.3 IgG-VLDx2 (LC)].
  • the bi-specific is shown binding to lysozyme immobilised on the biosensor surface followed with an addition of buffer at Point 1.
  • Trace 4 is a sensorgram of the bi-specific D1.3 anti-lysozyme antibody with VLDs coupled to the antibody CL chains [the bi-specific—D1.3 IgG-VLDx2 (LC)].
  • the bi-specific is shown binding to lysozyme immobilised on the biosensor surface followed by an addition of B7-1-Fc at Point 1.
  • B7-1-Fc was replaced with Buffer at Point 2.
  • FIG. 12 shows preliminary analysis using the ForteBio Blitz biosensor to demonstrate binding of the tri-specific [IgG VLDx4 (HC+LC)] to streptavidin captured biotin labelled lysozyme followed by secondary binding to B7-1-Fc.
  • the tri-specific has B7-1 binding VLDs coupled to both the D1.3 antibody [D1.3 IgG] heavy chains and light chains.
  • Trace 1 is a sensorgram of the D1.3 anti-lysozyme antibody [D1.3 IgG] used to construct the bi-specific. The antibody is shown binding to lysozyme immobilised on the biosensor surface followed by an addition of Buffer at Point 1.
  • Trace 2 is a sensorgram of the D1.3 anti-lysozyme antibody [D1.3 IgG] used to construct the bi-specific.
  • the antibody is shown binding to lysozyme immobilised on the biosensor surface followed by an addition of B7-1-Fc at Point 1.
  • B7-1-Fc was replaced with Buffer at Point 2.
  • Trace 3 is a sensorgram of the tri-specific D1.3 anti-lysozyme antibody with VLDs coupled to the antibody CH and CL chains [the tri-specific—D1.3 IgG-VLDx4 (HCLC)].
  • the tri-specific is shown binding to lysozyme immobilised on the biosensor surface followed with an addition of buffer at Point 1.
  • Trace 4 is a sensorgram of the tri-specific D1.3 anti-lysozyme antibody with VLDs coupled to the antibody CH and CL chains [the tri-specific—D1.3 IgG-Imx4 (HC+LC)].
  • the tri-specific is shown binding to lysozyme immobilised on the biosensor surface followed by an addition of B7-1-Fc at Point 1.
  • B7-1-Fc was replaced with Buffer at Point 2.
  • FIG. 13 shows preliminary analysis using the ForteBio Blitz biosensor to demonstrate increased binding of the tri-specific molecule relative to the bi-specific molecule.
  • the figure demonstrates increased binding levels to B7-1-Fc of the tri-specific relative to the bi-specific.
  • An equivalent number of antibody, bi-specific and tri-specific molecules were captured on biotin labelled lysozyme attached to a biosensor surface followed by the addition of buffer or B7-1-Fc (at Point 1) to demonstrate increased binding capacity of the tri-specific relative to the bi-specific.
  • Trace 1 is the D1.3 anti-lysozyme antibody [D1.3 IgG] used to construct the bi-specific and tri-specific. The bound antibody is shown with Buffer only injected at Point 1.
  • Trace 2 is the D1.3 anti-lysozyme antibody [D1.3 IgG] shown with B7-1-Fc injected at Point 1 At Point 2, B7-1-Fc was replaced with Buffer.
  • Trace 3 is the bi-specific D1.3 anti-lysozyme antibody with VLDs fused to the antibody CL chains [the bi-specific—D1.3 IgG-VLDx2 (LC)]. The captured bi-specific is shown binding to B7-1-Fc which was injected at Point 1. At Point 2, B7-1-Fc was replaced with Buffer.
  • Trace 4 is the tri-specific D1.3 anti-lysozyme antibody with VLDs fused to the antibody CH and CL chains [the tri-specific—D1.3 IgG-VLDx4 (HCLC)]. The captured bi-specific is shown binding to B7-1-Fc which was injected at Point 1. At Point 2, B7-1-Fc was replaced with Buffer.
  • FIG. 14 shows binding of bi-specific [IgG VLDx2 (HC))] to streptavidin captured biotin labelled lysozyme followed by secondary binding to a concentration series of B7-1-Fc (50, 25, 12.5, 6.25, 3.125, 1.56 and 0 ⁇ g/ml) was determined by SPR analysis with the concentration series of SPR binding sensorgrams overlaid.
  • the bi-specific has B7-1 binding VLDs fused to the D1.3 antibody [D1.3 IgG] heavy chains as illustrated in FIG. 2 .
  • Bi-specific injected is the point at which the IgG VLDx2 (HC) is added to the sensor surface.
  • the trace shows the IgG VLDx2 (HC) binding to lysozyme immobilised on the biosensor surface.
  • Buffer injected 1 Point at which the injection of IgG VLDx2 (HC) is stopped and replaced with buffer.
  • the trace shows the dissociation of the IgG VLDx2 (HC) from the lysozyme immobilised on the biosensor surface.
  • B7-1-Fc injected Point at which the second analyte B7-1-Fc is added at specified concentrations (at 50, 25, 12.5, 6.25, 3.125, 1.56 and 0 u ⁇ g/ml).
  • the trace shows B7-1-Fc binding to the IgG VLDx2 (HC) that is still bound to the lysozyme immobilised on the biosensor surface.
  • Buffer injected 2 Point at which the injection of B7-1-Fc is stopped and replaced with buffer.
  • the trace shows the dissociation of B7-1-Fc from IgG VLDx2 (HC) still attached to the lysozyme immobilised on the biosensor surface.
  • FIG. 15 shows binding of the bi-specific [IgG VLDx2 (LC)] to streptavidin captured biotin labelled lysozyme followed by secondary binding to a concentration series of B7-1-Fc (at 50, 25, 12.5, 6.25, 3.125, 1.56 and 0 ⁇ ug/ml) was determined by SPR analysis with the concentration series of SPR binding sensorgrams overlaid.
  • the bi-specific has B7-1 binding VLDs fused to the D1.3 antibody [D1.3 IgG] light chains as illustrated in FIG. 3 .
  • Bi-specific injected Point at which the IgG VLDx2 (LC) is added to the sensor surface. The trace shows the IgG VLDx2 (LC) binding to lysozyme immobilised on the biosensor surface.
  • Buffer injected 1 Point at which the injection of IgG VLDx2 (LC) is stopped and replaced with buffer. The trace shows the dissociation of the IgG VLDx2 (LC) from the lysozyme immobilised on the biosensor surface.
  • B7-1-Fc injected Point at which the second analyte B7-1-Fc is added at specified concentrations (at 50, 25, 12.5, 6.25, 3.125, 1.56 and 0 ⁇ g/ml).
  • the trace shows B7-1-Fc binding to the IgG VLDx2 (LC) that is still bound to the lysozyme immobilised on the biosensor surface.
  • Buffer injected 2 Point at which the injection of B7-1-Fc is stopped and replaced with buffer.
  • the trace shows the dissociation of B7-1-Fc from IgG VLDx2 (LC) still attached to the lysozyme immobilised on the biosensor surface.
  • FIG. 16 shows binding of the tri-specific [IgG VLDx4 (HC+LC)] to streptavidin captured biotin labelled lysozyme followed by secondary binding to a concentration series of B7-1-Fc (at 25, 12.5, 6.25, 3.125, 1.56 and 0 ⁇ g/ml) was determined by SPR analysis with the concentration series of SPR binding sensorgrams overlaid.
  • the tri-specific has B7-1 binding VLDs fused to both the D1.3 antibody [D1.3 IgG] heavy and light chains as illustrated in FIG. 4 .
  • Tri-specific injected Point at which the IgG VLDx4 (HC+LC) is added to the sensor surface.
  • the trace shows the IgG Imx4 (HCLC) binding to lysozyme immobilised on the biosensor surface.
  • Buffer injected 1 Point at which the injection of IgG VLDx4 (HC+LC) is stopped and replaced with buffer.
  • the trace shows the dissociation of the IgG VLDx4 (HC+LC) from the lysozyme immobilised on the biosensor surface
  • B7-1-Fc injected Point at which the second analyte B7-1-Fc is added at specified concentrations (at 25, 12.5, 6.25, 3.125, 1.56 and 0 ⁇ g/ml).
  • the trace shows B7-1-Fc binding to the IgG VLDx4 (HC+LC) that is still bound to the lysozyme immobilised on the biosensor surface.
  • Buffer injected 2 Point at which the injection of B7-1-Fc is stopped and replaced with buffer.
  • the trace shows the dissociation of B7-1-Fc from IgG VLDx4 (HC+LC) still attached to the lysozyme immobilised on the biosensor surface
  • the binding properties of the purified Fab, Fab-VLD bi-specific and tri-specific molecules were also characterised using surface plasmon resonance (SPR).
  • FIG. 17 shows a series of SPR binding sensorgrams that have been overlaid demonstrating initial binding of the bi-specific [Fab-VLDx1 (HC)] to streptavidin captured biotin labelled lysozyme followed by secondary binding to a concentration series of B7-1-Fc (at 25, 12.5, 6.25, 3.125, 1.56 and 0 ug/ml).
  • the bi-specific has a B7-1 binding VLD fused to the D1.3 Fab [D1.3 Fab] heavy chain as illustrated in FIG. 5 .
  • Bi-specific Injected Point at which the Fab-VLDx1 (HC) is added to the sensor surface.
  • the trace shows the Fab-VLDx1(HC) binding to lysozyme immobilised on the biosensor surface.
  • Buffer Injected 1 Point at which the injection of Fab-VLDx1(HC) is stopped and replaced with buffer.
  • the trace shows the dissociation of the Fab-VLDx1(HC) from the lysozyme immobilised on the biosensor surface
  • B7-1-Fc Injected Point at which the second analyte B7-1-Fc is added at specified concentrations (at 25, 12.5, 6.25, 3.125, 1.56 and 0 ug/ml).
  • the trace shows B7-1-Fc binding to the Fab-VLDx1 (HC) that is still bound to the lysozyme immobilised on the biosensor surface.
  • Buffer Injected 2 Point at which the injection of B7-1-Fc is stopped and replaced with buffer. The trace shows the dissociation of B7-1-Fc from Fab-VLDx1(HC) still attached to the lysozyme immobilised on the biosensor surface.
  • FIG. 18 shows a series of SPR binding sensorgrams that have been overlaid demonstrating initial binding of the bi-specific [Fab-VLDx1 (LC)] to streptavidin captured biotin labelled lysozyme followed by secondary binding to a concentration series of B7-1-Fc (at 25, 12.5, 6.25, 3.125, 1.56 and 0 ug/ml).
  • the bi-specific has a B7-1 binding VLD fused to the D1.3 Fab [D1.3 Fab] light chain as illustrated in FIG. 6 .
  • Bi-specific Injected Point at which the Fab-VLDx1 (LC) is added to the sensor surface. The trace shows the Fab-VLDx1 (LC) binding to lysozyme immobilised on the biosensor surface.
  • Buffer Injected 1 Point at which the injection of Fab-VLDx1 (LC) is stopped and replaced with buffer. The trace shows the dissociation of the Fab-VLDx1 (LC) from the lysozyme immobilised on the biosensor surface.
  • B7-1-Fc Injected Point at which the second analyte B7-1-Fc is added at specified concentrations (at 25, 12.5, 6.25, 3.125, 1.56 and 0 ug/ml).
  • the trace shows B7-1-Fc binding to the Fab-VLDx1 (LC) that is still bound to the lysozyme immobilised on the biosensor surface.
  • Buffer Injected 2 Point at which the injection of B7-1-Fc is stopped and replaced with buffer.
  • the trace shows the dissociation of B7-1-Fc from Fab-VLDx1 (LC) still attached to the lysozyme immobilised on the biosensor surface.
  • FIG. 19 shows a series of SPR binding sensorgrams that have been overlaid demonstrating initial binding of the tri-specific [Fab-VLDx2(HC+LC)] to streptavidin captured biotin labelled lysozyme followed by secondary binding to a concentration series of B7-1-Fc (at 25, 12.5, 6.25, 3.125, 1.56 and 0 ⁇ g/ml).
  • the tri-specific has B7-1 binding VLDs fused to both the D1.3 Fab [D1.3 Fab] heavy and light chains as illustrated in FIG. 7 .
  • Tri-specific Injected Point at which the Fab-VLDx2(HC+LC) is added to the sensor surface.
  • the trace shows the Fab-VLDx2(HC+LC) binding to lysozyme immobilised on the biosensor surface.
  • Buffer Injected 1 Point at which the injection of Fab-VLDx2(HC+LC) is stopped and replaced with buffer.
  • the trace shows the dissociation of the Fab-VLDx2(HC+LC) from the lysozyme immobilised on the biosensor surface
  • B7-1-Fc Injected Point at which the second analyte B7-1-Fc is added at specified concentrations (at 25, 12.5, 6.25, 3.125, 1.56 and 0 ⁇ g/ml).
  • the trace shows B7-1-Fc binding to the Fab-VLDx2(HC+LC) that is still bound to the lysozyme immobilised on the biosensor surface.
  • Buffer injected 2 Point at which the injection of B7-1-Fc is stopped and replaced with buffer.
  • the trace shows the dissociation of B7-1-Fc from Fab-VLDx2(HC+LC) still attached to the lysozyme immobilised on the biosensor surface.
  • Binding stoichiometry of the bi-specific [IgG VLDx2 (HC)] and tri-specific [IgG Imx4 (HC+LC)] for B7-1-Fc were also determined by SPR ( FIG. 20 ).
  • the kinetic assays were performed for IgG-VLDx2 (HC), IgG-VLDx2 (LC) and IgG-VLDx4 (HCLC) by capturing on a biotin-lysozyme surface, and running a series of concentrations of B7-1-Fc (50, 25, 12.5, 6.25, 3.125, 1.56 and 0 ⁇ g/ml) as the analyte.
  • the theoretical maximum binding signal for the analyte (Rmax) was calculated based on the amount of captured IgG-VLD protein, accounting for the molecular weight of the analyte and ligand.
  • the binding level of analyte to ligand was plotted as a percentage of the Rmax value, for each concentration. As the analyte concentration increased to 25 ⁇ g/ml, the binding levels neared saturation or equilibrium levels.
  • the equilibrium binding level for the tetravalent protein, IgG-VLDx4(HC+LC) (103.9% of Rmax) was around double that of the bivalent proteins IgG-VLDx2(HC) (56.7%) and IgG-VLDx2(LC) (51.4%). This suggests that IgG-VLDx4(HC+LC) is able to bind B7.1-Fc through the heavy and light chain-fused VLD domains simultaneously.
  • the binding kinetics of the antibody-VLD bi-specific and tri-specific molecules and the Fab-VLD bi-specific and tri-specific molecules was determined by surface plasmon resonance.
  • the association constant (Ka), dissociation constant (Kd) and equilibrium dissociation constant/binding constant K D are shown in Tables 3 and 4 respectively.
  • the IgG VLDx4 (HCLC) construct was modified whereby sclerostin (Scl) binding VLDs were coupled to the C terminus of the heavy chains of the anti-lysozyme antibody D1.3 and B7-1 binding VLDs were coupled to the antibody constant light (CL) chains of an anti-lysozyme antibody.
  • This tri-specific molecule was designated [IgG VLDx4 (Scl-HC)(B7-LC)].
  • sequence of the anti-Lysozyme IgG1 heavy chain fused to anti-Sclerostin VLD ‘1E1’ is shown below (SEQ ID NO:25):
  • VLD binding loops of SEQ ID NO:25 and SEQ ID NO:14 are underlined.
  • sclerostin R&D Systems catalogue number 1406-ST/CF
  • sclerostin R&D Systems catalogue number 1406-ST/CF
  • the surface was regenerated by injecting 10 mM Glycine buffer at pH 2.1 for 30 seconds.
  • FIG. 22 shows a series of SPR binding sensorgrams that have been overlaid demonstrating initial binding of the tri-specific [IgG VLDx4 (Scl-HC)(B7-LC)] to streptavidin captured biotin labelled lysozyme followed by simultaneous binding to B7-1-Fc and sclerostin.
  • the tri-specific has sclerostin binding VLDs fused to the D1.3 antibody [D1.3 IgG] heavy chains and B7-1 binding VLD's fused to the light chains.
  • the B7-1-Fc only trace is a sensorgram of the tri-specific showing binding to lysozyme immobilised on the biosensor surface followed by the addition of B7-1-Fc.
  • the sensorgram demonstrates simultaneous, dual target binding to lysozyme and B7-1-Fc.
  • the Sclerostin only trace is a sensorgram of the tri-specific showing binding to lysozyme immobilised on the biosensor surface followed by the addition of sclerostin.
  • the sensorgram demonstrates simultaneous, dual target binding to lysozyme and sclerostin.
  • the B7-1-Fc and Sclerostin trace is a sensorgram of the tri-specific showing binding to lysozyme immobilised on the biosensor surface followed by the addition of B7-1-Fc, and then followed by the addition of sclerostin.
  • the sensorgram demonstrates simultaneous, trio target binding to lysozyme and B7-1-Fc and sclerostin.
  • Binding of the molecule to B7-1 and sclerostin was examined by SPR as shown in FIG. 22 .
  • the results show that the tri-specific was capable of simultaneous binding to both B7-1 and sclerostin.
  • the Fab VLDx2 (HC+LC) construct was modified whereby a B7-1 binding VLD was coupled to the C terminus of the heavy chain of the anti-lysozyme Fab D3.1 and a sclerostin (Scl) binding VLD was coupled to the Fab constant light (CL) chain of an anti-lysozyme Fab.
  • This tri-specific molecule was designated [Fab VLDx2 (B7-1-HC)(Scl-LC)].
  • a second construct was made whereby a sclerostin binding VLD was coupled to the C terminus of the heavy chain of the anti-lysozyme Fab D3.1 and a B7-1 binding VLD was coupled to the Fab constant light (CL) chain of an anti-lysozyme Fab.
  • This tri-specific molecule was designated [Fab VLDx2 (Scl-HC)(B7-1-LC)]
  • FIG. 23 shows binding analysis for the tri-specific Fab VLDx2 (B7-1-HC)(Scl-LC) and FIG. 24 shows the binding analysis for the tri-specific Fab VLDx2 (Scl-HC)(B7-1-LC). Binding analysis was performed using the ForteBio Blitz. The binding traces demonstrate initial binding of the tri-specifics (Fab VLDx2 (B7-HC)(Scl-LC) in FIG. 23 and Fab VLDx2 (Scl-HC)(B7-1-LC) in FIG. 24 ) to streptavidin captured biotin labelled lysozyme followed by sequential and simultaneous binding to B7-1-Fc and sclerostin.
  • the biosensor traces show the tri-specifics initially binding to lysozyme immobilised on the biosensor surface followed by binding to B7-1-Fc (B7-1-Fc was added at the point indicated).
  • the binding traces demonstrate simultaneous, dual target binding to lysozyme and B7-1-Fc.
  • Sclerostin is subsequently added at the point indicated and the biosensor trace shows simultaneous, tri-target binding to lysozyme and B7-1-Fc and sclerostin for both the Fab VLDx2 (B7-1-HC)(Scl-LC) and Fab VLDx2 (Scl-HC)(B7-1-LC) molecules.
  • sclerostin is replaced with buffer to show the dissociation rate.
  • FIG. 25 shows a schematic of a protein coupled to a VLD according to one example of the disclosure.
  • the bi-specific can bind to both Target A and B either individually or at the same time.
  • Sequences encoding human serum albumin (HSA) fused to one or two VLDs were produced, including a 16 amino acid linker sequence (SGGGGSGGGGSGGGGS) highlighted and a C-terminal histidine tag.
  • the sequences were cloned into a mammalian expression vector.
  • the vector used was the pcDNA3.4 vector (Thermo Fisher).
  • the sequences were cloned with a signal peptide to allow the protein to be secreted.
  • the sequence of the peptide was as follows MAWMMLLLGLLAYGSG (SEQ ID NO:8).
  • Vector transformation of bacteria was performed according to standard techniques using electroporation competent cells (e.g. ElectroTen-Blue cells, Stratagene Cat #200159).
  • Plasmid DNA was extracted and prepared using Qiagen HiSpeed Plasmid Maxi Kit (Cat # 12663) or Promega PureYieldTM Plasmid Midiprep System (Cat # A2492). DNA was eluted in nuclease free purified water.
  • the proteins were purified by affinity chromatography using Nickel Sepharose Excel (GE, Cat # 17-3712-01).
  • a Nickel Sepharose column was equilibrated with 5 column volumes of 20 mM sodium phosphate, 0.5 M NaCl, ph7.4.
  • the transfected cell culture supernatant containing the His-tagged HSA-VLD protein was loaded onto the column, and the column was washed with 10 column volumes of 20 mM sodium phosphate, 0.5 M NaCl, 5 mM imidazole, ph7.4.
  • the protein was eluted with 20mM sodium phosphate, 0.5 M NaCl, 500 mM imidazole ph7.4.
  • the eluted fractions were pooled and dialysed with PBS according to standard methods.
  • FIG. 26 shows western blot analysis and detection with anti-His HRP (Sigma Aldrich, Cat # 11965085001) of the purified HSA fusion proteins, which comprise of VLDs fused to the C-terminus, the N-terminus, or both the C-terminus and N-terminus of HSA.
  • the estimated sizes of the proteins, respectively, are: 67 kDa (predicted size: 81.9 kDa); 69.3 kDa (predicted size: 81.8 kDa); and 94.4 kDa (predicted size: 96.2 kDa).
  • the binding properties of the purified molecules were characterised using the ForteBio Blitz biosensor using standard chemistry and reagents.
  • the affinity purified molecules were tested with commercially available B7.2-Fc protein (R&D Systems, Cat# 141-B2), CD3 (Acrobiosystems, Cat# CDD-H52W3), and biotinylated anti-HSA affibody (Abcam, Cat # 31898).
  • CD3 and B7.2Fc proteins were biotinylated at 1:1 molar ratio using EZ-Link Sulfo-NHS-LC-Biotin (ThermoFisher, Cat # 21327) according to standard methods.
  • a streptavidin capturing surface (SA Sensor, ForteBio cat# 18-5019) was used to capture biotin labelled protein.
  • the HSA-VLD molecule was passed over the target captured on the biosensor surface to generate a binding sensorgram.
  • FIG. 27 shows analysis using the ForteBio Blitz biosensor to demonstrate binding of the HSA-VLD molecules to streptavidin captured biotin labelled B7.2-Fc.
  • Trace 1 is a sensorgram of the HSA-VLD fusion protein, which has a B7-binding VLD attached to the C-terminus.
  • Trace 2 is a sensorgram of the VLD-HSA-VLD fusion protein, which has a B7-binding VLD attached to both the N-terminus and the C-terminus. The molecules are shown binding to B7.2-Fc immobilised on the biosensor surface followed by an addition of Buffer at Point 1.
  • FIG. 28 shows analysis using the ForteBio Blitz biosensor to demonstrate binding of the HSA-VLD molecule to streptavidin captured biotin labelled CD3 delta/epsilon (de) heterodimer.
  • the trace shown is a sensorgram of the HSA-VLD fusion protein, which has a CD3-binding VLD attached to the C-terminus.
  • the molecule is shown binding to CD3de immobilised on the biosensor surface followed by an addition of Buffer at Point 1.
  • FIG. 29 shows analysis using the ForteBio Blitz biosensor to demonstrate binding of the HSA-VLD molecule to streptavidin captured biotin labelled anti-HSA affibody.
  • the trace shown is a sensorgram of the HSA-VLD fusion protein, which has a B7-binding VLD attached to the C-terminus.
  • the molecule is shown binding to anti-HSA affibody immobilised on the biosensor surface followed by an addition of Buffer at Point 1.
  • B7.2Fc protein was allowed to bind to the captured molecules on the sensor surface. B7.2Fc was then replaced with buffer at Point 3.
  • CD3 Binding VLD (Referred to as AF3) Fused to the C-Terminus of Human Serum Albumin
  • CD3-binding VLD “AF3” fused to the C-terminus of HSA (SEQ ID NO: 29): DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCD KSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCT AFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEG KASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLL ECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDV CKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFK PLVEEPQNLIKQNCELF

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
US16/079,949 2016-02-26 2017-02-27 Multi-Specific Molecules Abandoned US20190338013A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2016900708A AU2016900708A0 (en) 2016-02-26 Multi-specific molecules 1
AU2016900709 2016-02-26
AU2016900708 2016-02-26
AU2016900709A AU2016900709A0 (en) 2016-02-26 Multi-specific molecules 2
PCT/AU2017/050168 WO2017143406A1 (en) 2016-02-26 2017-02-27 Multi-specific molecules

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2017/050168 A-371-Of-International WO2017143406A1 (en) 2016-02-26 2017-02-27 Multi-specific molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/946,451 Continuation US20210040177A1 (en) 2016-02-26 2020-06-22 Multi-Specific Molecules

Publications (1)

Publication Number Publication Date
US20190338013A1 true US20190338013A1 (en) 2019-11-07

Family

ID=59685848

Family Applications (4)

Application Number Title Priority Date Filing Date
US16/079,949 Abandoned US20190338013A1 (en) 2016-02-26 2017-02-27 Multi-Specific Molecules
US16/946,451 Abandoned US20210040177A1 (en) 2016-02-26 2020-06-22 Multi-Specific Molecules
US17/223,935 Active US11345736B2 (en) 2016-02-26 2021-04-06 Multi-specific molecules
US18/239,052 Pending US20240182542A1 (en) 2016-02-26 2023-08-28 Multi-Specific Molecules

Family Applications After (3)

Application Number Title Priority Date Filing Date
US16/946,451 Abandoned US20210040177A1 (en) 2016-02-26 2020-06-22 Multi-Specific Molecules
US17/223,935 Active US11345736B2 (en) 2016-02-26 2021-04-06 Multi-specific molecules
US18/239,052 Pending US20240182542A1 (en) 2016-02-26 2023-08-28 Multi-Specific Molecules

Country Status (7)

Country Link
US (4) US20190338013A1 (enExample)
EP (1) EP3419667A4 (enExample)
JP (3) JP7536424B2 (enExample)
CN (1) CN109310766A (enExample)
AU (2) AU2017222700B2 (enExample)
TW (1) TW201734037A (enExample)
WO (1) WO2017143406A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022081529A1 (en) * 2020-10-12 2022-04-21 Greffex, Inc. Antibody constructs to target t cell responses to sars-cov protein expressing cells, their design and uses

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017143406A1 (en) * 2016-02-26 2017-08-31 Imunexus Pty Ltd Multi-specific molecules
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
ES2955074T3 (es) 2017-02-20 2023-11-28 Dragonfly Therapeutics Inc Proteínas que se unen a HER2, NKG2D Y CD16
MX2019013648A (es) 2017-05-19 2021-01-08 Wuxi Biologics Shanghai Co Ltd Anticuerpos monoclonales novedosos para proteina 4 asociada con el linfocito t citotoxico (ctla-4).
EP3668893A4 (en) * 2017-08-16 2021-08-04 Dragonfly Therapeutics, Inc. PROTEINS BINDING TO NKG2D, CD16 AND EGFR, HLA-E, CCR4, OR PD-L1
CN117050184A (zh) 2017-12-28 2023-11-14 南京传奇生物科技有限公司 针对tigit的单域抗体和其变体
TW201930349A (zh) * 2018-01-08 2019-08-01 大陸商南京傳奇生物科技有限公司 多重特異性抗原結合蛋白及其使用方法
JP7366908B2 (ja) 2018-01-15 2023-10-23 ナンジン レジェンド バイオテック カンパニー，リミテッド Ｐｄ－１に対する単一ドメイン抗体及びその変異体
CA3090236A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
SG11202007482WA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Antibody variable domains targeting the nkg2d receptor
KR102832460B1 (ko) 2018-02-20 2025-07-11 드래곤플라이 쎄라퓨틱스, 인크. Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
MA53293A (fr) 2018-08-08 2021-11-17 Dragonfly Therapeutics Inc Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation
MX2021001527A (es) 2018-08-08 2021-06-15 Dragonfly Therapeutics Inc Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor.
BR112021012631A2 (pt) 2018-12-26 2021-12-14 Xilio Dev Inc Anticorpos anti-ctla4 e métodos de uso dos mesmos
KR20210131373A (ko) * 2019-02-18 2021-11-02 커리어 테라퓨틱스, 인코포레이티드. 오르토폭스바이러스 주요 조직적합성 복합체(mhc) 클래스 i-유사 단백질(omcp) 및 종양-특이 결합 파트너를 사용한 이중특이적 융합 단백질
JP2022527761A (ja) * 2019-03-26 2022-06-06 フォーティ セブン， インコーポレイテッド がん治療のための多重特異性作用物質
EP3816185A1 (en) * 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
EP4093745A4 (en) * 2020-01-20 2024-03-06 Wuxi Biologics Ireland Limited NEW WASH BUFFER SOLUTION FOR AFFINITY CHROMATOGRAPHY
MX2022013944A (es) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
US20250345423A1 (en) * 2021-11-26 2025-11-13 Imunexus Therapeutics Limited Binding domain molecules on cell surfaces
CN115078718B (zh) * 2022-07-22 2024-11-12 福建师范大学 一种基于表面增强拉曼技术检测透明质酸酶的方法
EP4615859A2 (en) * 2022-11-09 2025-09-17 Repligen Corporation Affinity agents

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP221098A0 (en) * 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
EP1163339A1 (en) * 1999-04-01 2001-12-19 Innogenetics N.V. A polypeptide structure for use as a scaffold
US20100081792A1 (en) * 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
DE112008003232T5 (de) * 2007-11-30 2011-02-24 Glaxo Group Limited, Greenford Antigen-Bindungskonstrukte
HRP20180045T1 (hr) * 2008-10-02 2018-03-23 Aptevo Research And Development Llc Proteini antagonisti cd86 koji se vežu na više meta
CA2763493A1 (en) * 2009-05-28 2010-12-02 Glaxo Group Ltd. Antigen-binding proteins
CN102458471A (zh) 2009-05-28 2012-05-16 葛兰素集团有限公司 用于治疗或预防眼病的TNFα拮抗剂和VEGF拮抗剂的组合
WO2017143406A1 (en) * 2016-02-26 2017-08-31 Imunexus Pty Ltd Multi-specific molecules

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022081529A1 (en) * 2020-10-12 2022-04-21 Greffex, Inc. Antibody constructs to target t cell responses to sars-cov protein expressing cells, their design and uses

Also Published As

Publication number Publication date
JP2022105574A (ja) 2022-07-14
CN109310766A (zh) 2019-02-05
US20240182542A1 (en) 2024-06-06
TW201734037A (zh) 2017-10-01
US20210230249A1 (en) 2021-07-29
US20210040177A1 (en) 2021-02-11
AU2017222700B2 (en) 2018-09-27
EP3419667A1 (en) 2019-01-02
JP7536424B2 (ja) 2024-08-20
EP3419667A4 (en) 2019-10-23
AU2017222700A1 (en) 2018-03-22
WO2017143406A1 (en) 2017-08-31
AU2019200005A1 (en) 2019-01-24
JP2019510812A (ja) 2019-04-18
JP2024026531A (ja) 2024-02-28
US11345736B2 (en) 2022-05-31

Similar Documents

Publication Publication Date Title
US11345736B2 (en) Multi-specific molecules
US20250295767A1 (en) Ror1-specific antigen binding molecules
CN116761815A (zh) T细胞和嵌合刺激受体及其应用
US8329183B2 (en) Recombinant fusion protein and polynucleotide construct for immunotoxin production
JP2019523651A (ja) 抗ｐｓｍａ抗体およびその使用
US11912771B2 (en) MAGE-A4 peptide-MHC antigen binding proteins
US20230203167A1 (en) Anti-pd-l1 and pd-l2 antibody and derivatives and use thereof
KR20220161362A (ko) 다중특이적 항체를 작제하기 위한 플랫폼
CN117964767B (zh) 抗rage抗体、细胞外囊泡及其制备方法和应用
JP2024100838A (ja) 抗ラムダ骨髄腫抗原（ｌｍａ）発現がん及び自己免疫障害を処置するｌｍａ結合タンパク質
US20240101680A1 (en) Antibodies Targeting Integrin Beta-2
KR20250085636A (ko) 신규 항-myct1 인간항체 및 이의 용도
WO2025148933A1 (zh) 抗体及其药物偶联物和用途
WO2025146128A1 (zh) 抗liv-1的抗体及其用途
KR20250001441A (ko) 인간화 항-myct1 항체 및 이의 용도
WO2025215160A1 (en) Antigen binding proteins targeting an hla-restricted prame peptide
US8597655B2 (en) Recombinant fusion protein and polynucleotide construct for immunotoxin production
CN117751146A (zh) Mage-a4肽-mhc抗原结合蛋白

Legal Events

Date Code Title Description
AS Assignment

Owner name: IMUNEXUS PTY LTD., AUSTRALIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ROBERTS, ANTHONY;KOPSIDAS, GEORGE;LUKE, MICHAEL;AND OTHERS;SIGNING DATES FROM 20160103 TO 20170608;REEL/FRAME:047156/0055

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION